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Patient safety has received considerable public, professional, political, and sci-
entific attention over the past decades (1). Healthcare-associated infections 
(HAIs) are infections that patients acquire while receiving treatment for medical 
or surgical conditions and are among the most common adverse events in 
healthcare contributing to increased morbidity, mortality, and healthcare costs 
(2, 3). The European Centers for Disease Control and Prevention (ECDC) esti-
mated that 3.2 million patients are affected by at least one HAI episode per year 
in acute care hospitals in Europe (4). 
HAI surveillance is the cornerstone of prevention and control since it facili-
tates the development of appropriate intervention measures and helps to evalu-
ate their efficacy (5). Systems have been set up in different countries in order to 
describe and monitor HAIs; some of them were implemented several decades 
ago (6). Since 2008 ECDC has continuous surveillance system for HAIs in 
intensive care unit (ICU) and surgical site infections (SSIs) (7).  
The most common types of HAIs are lower respiratory tract infections 
(LRTIs), urinary tract infections (UTIs), SSIs and bloodstream infections (BSIs) 
(4). Overall rates of HAI vary widely in different populations as the result of 
differences in distribution of the major intrinsic and extrinsic risk factors for the 
acquisition of HAIs, with the highest rates usually occurring in ICUs (3). The 
most vulnerable pediatric population are the patients in neonatal ICU (NICU) or 
in pediatric ICU (PICU), where BSI is the most common HAI leading to in-
creased morbidity, mortality and long-term consequences (8). 
Surveillance of HAI is also important in other wards besides ICU, but it is 
complicated and expensive to perform surveillance of all HAI (9). Hospital-
wide surveillance of nosocomial BSI may have an advantage over other types of 
infection data as they represent the severe end of the spectrum of infection. 
Surveillance of nosocomial BSI is thought to be useful in monitoring trends of 
HAIs, identifying wards at risk, outbreaks and emerging multiresistant patho-
gens, and effects of HAI intervention programs (10). Up-to-date information on 
species distribution and patterns of antimicrobial resistance is also essential for 
drawing up guidelines of empiric antimicrobial treatment (11). 
While BSIs are more likely to be associated with life-threatening illness or 
even death, SSI remains among the most common infections occurring in acute 
care hospitals (12, 13). In the point prevalence survey of HAI and antimicrobial 
use in European acute care hospitals, SSI were the second most common type of 
HAI and accounted for 19.6% of all infections (4). Since the length of post-
operative hospitalization continues to decrease, the increasing number of SSI is 
not detected through standard surveillance method and therefore postdischarge 
SSI surveillance has become increasingly important in order to obtain accurate 
SSI rates (14). Several methods for postdischarge surveillance of SSI have been 
evaluated for efficiency (15). Nevertheless, there is no universally accepted 
strategy for monitoring these infections and postdischarge surveillance methods 
and practices differ considerably among countries (16). 
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In Estonia, before 2002 some studies investigated hospital-acquired micro-
organisms such as Acinetobacter baumannii, Staphylococcus aureus and Esche-
richia coli (17, 18). There was no surveillance system of HAI and no study of 
the epidemiology of HAIs was carried out. This research was performed to 
assess the epidemiological features of nosocomial BSIs and SSIs: the risk fac-
tors, species distribution, and the antimicrobial susceptibility of causative path-
ogens. We also evaluated a multimethod approach to postdischarge surveillance 






2. REVIEW OF LITERATURE 
2.1. Epidemiology of healthcare-associated  
infections and burden to public health 
2.1.1. Definition of healthcare-associated infection 
The use of standardized definitions is crucial to the reliability of HAI surveil-
lance (3). These definitions should be precise and easily applicable that would 
enable different researchers to compare their results. 
In 1988 the Centers for Disease Control and Prevention developed new set 
of definitions for surveillance of nosocomial infections. “Nosocomial” or “hos-
pital-acquired” infection, is an infection occurring in a patient during the pro-
cess of care in a hospital which was not present or incubating at the time of 
admission (19). In acute care setting, most nosocomial infections become evi-
dent 48 hours or more following admission (typical incubation period), which 
resulted in the use of the 48-hours criterion in several epidemiological surveil-
lance systems (3). Different HAIs have been grouped into 14 major type catego-
ries according to the localization (20). The US CDC definitions are widely used 
around the world. Since 2008 HAI surveillance activities in Europe have been 
coordinated by ECDC and the network was named the Healthcare-Associated 
Infections surveillance Network (HAI-Net) (7). The ECDC analyzed the 
concordance between the US CDC and ECDC definitions of HAI and identified 
that case definitions do not differ significantly and do not compromise compa-
rability of results (7).  
However, in the last decade, there has been a shift in the delivery of health-
care services such that increasingly complex medical and surgical services are 
being provided in non-acute-care settings or in the community (21). As a result, 
community based patients may now be admitted to hospital with infections that 
share many characteristics with hospital-acquired infections (22). In addition, 
patients move freely within elements of the health care system: between long-
term care or rehabilitation facilities, to acute-care facilities, to free-standing 
surgical care providers, making the definition of a health care setting more 
problematic (21). The term “HAI” has replaced the former ones used to refer to 
such infections, i.e., “nosocomial” or “hospital-acquired” infection, as evidence 
has shown that this event can affect patients in any settings where they receive 
care (3). In addition to the original definition of nosocomial infection, the most 
widely accepted definition of HAI in literature, primarily developed for BSI, 
encompasses infectious diseases in patients who fulfil one or more of the 
following criteria (23): 
1. Resident in a nursing home or a long-term care facility. 
2. Intravenous therapy at home or wound care or specialized nursing care. 
3. Having attended a hospital or hemodialysis clinic or received intravenous 
chemotherapy in the past 30 days. 




The proportion of patients hospitalized with HAI among those admitted from 
the community setting can be as high as 50% (23).  
Furthermore, HAIs are not restricted only to patients; health-care workers, 
ancillary staff, and visitors can also be affected (3). 
 
 
2.1.2. Morbidity and mortality of healthcare-associated infections 
In 2011–2012 the first Europe-wide point prevalence survey of HAIs and anti-
microbial use estimated that on any given day, about 80 000 patients in Euro-
pean hospitals have at least one HAI with a mean HAI prevalence of 6.0% 
(country range 2.3%–10.8%) (4). In Europe, the most frequently reported HAI 
types were pneumonia and other LRTIs (19.4% and 4.1% respectively), SSIs 
(19.6%), UTIs (19.0%), BSIs (10.6%) and gastrointestinal infections (7.6%) 
with C. difficile infections accounting for 48% of the latter or 3.6% of all HAIs 
(4). The HAI prevalence rate in the USA was 4.0% in acute care hospitals yield-
ing an estimate of 648 000 inpatients with a total of approximately 721 800 
such infections in 2011 (24). The most common types were pneumonia 
(21.8%), SSIs (21.8%), gastrointestinal infections (17.1%), UTIs (12.9%), and 
BSIs (9.9%) (24). 
The HAI burden is much more severe in high-risk populations, such as pa-
tients admitted to ICUs, burn and transplant patients, and neonates (3). In 
ECDC point prevalence survey the prevalence of HAI ranged from 0.9% in 
psychiatry to 19.5% in ICUs (4). 
Overall rates of HAI vary widely in different pediatric populations as the re-
sult of differences in distribution of the major intrinsic and extrinsic risk factors 
for the acquisition of HAIs. The pediatric population with the largest number of 
these risk factors, and thus the highest rates of HAIs, are patients in NICUs or in 
PICUs (25). A European study of 17 pediatric centers reported an overall HAI 
incidence of 2.5% (from 1% in general pediatric wards to 23.6% in PICUs) 
including five types of HAI: BSIs (36% of all infections), LRTIs (33%), gas-
trointestinal infections (14%), UTIs (11%), and SSIs (6%) (26). The US point 
prevalence survey of HAI in 29 NICUs and 35 PICUs revealed an overall HAI 
prevalence of 11.4% and 11.9%, respectively (27, 28). Pediatric patients have 
higher rates of BSIs (the most common HAI in all pediatric age groups) and 
viral gastrointestinal and respiratory infections than adult patients, whereas rates 
of catheter-related UTIs, ventilator-associated pneumonia (VAP), and SSI are 
higher in adult patients (29).  
In Europe HAIs are estimated to cause 37 000 attributable deaths annually 
(3). Among the 1.7 million patients with HAI in the US there were approxi-
mately 99 000 deaths per year caused by or associated with the HAI, making 
HAIs the fifth leading cause of death in acute care hospital (2, 21).  
The percentage of patients whose deaths are associated with an HAI varies 
by major site of infection and subpopulation. According to several studies 
performed in high-income countries some infections, e.g., VAP and BSI, have a 
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more severe impact on patient outcome than others (3). In US it was estimated 
that pneumonia and BSI caused 67% of all deaths (2). In the same study the 
highest percentage of patients with an HAI whose death was associated with the 
infection was among adults and children in ICUs where the percentage varied 
from 11% for SSIs to 25% for BSIs (2). According to the 2003–2008 
International Infection Control Consortium report related to 173 ICUs in Latin 
America, Asia, Africa, and Europe crude excess mortality in adult patients was 
18.5%, 23.6% and 29.3% for UTI, BSI and VAP, respectively (30). In pediatric 
setting BSI carries the highest mortality and neonates are the age-group at 
highest risk for poor outcome (31). Additionally and equally important, 
neonatal HAIs can have long-term sequelae including poor neurodevelopmental 
and growth outcomes (32). 
Estimating the excess mortality due to HAI is challenging, especially in 
high-risk patients who are at greater risk of death because of severe underlying 
diseases (3). For example, different methods have been used to calculate the 
attributable mortality of VAP, yielding estimates up to 60% (33). On the basis 
of a recently published meta-analysis of 6284 individual patients’ data from 24 
trials of VAP prevention Melsen and colleagues estimated that the attributable 
mortality of VAP was only 13% (33). Nevertheless, patients who acquire HAI 
have an excess risk to death. 
 
 
2.1.3. Costs of healthcare-associated infections 
HAIs induce high costs which are difficult to measure with accuracy. The direct 
financial impact of HAIs on the healthcare budget is predominantly determined 
through an increased number of readmissions, length of hospitalization (e.g., 
about 1–4 extra days for a UTI, 7–8 days for a SSI, 7–21 days for a BSI, and 7–
30 days for pneumonia), use of antimicrobials, surveillance and isolation 
measures, laboratory and imaging services attributable to diagnosing and man-
aging HAIs, and costs attributable to outbreaks (34). 
According to the recently published US data, annual costs for the 5 major 
HAIs was $9.8 billion. On a per-case basis, central line associated bloodstream 
infections (CLABSIs) were found to be the most costly HAIs at $45 814 (95% 
confidence interval 95% CI, $30 919–$65 245), followed by VAP at $40 144 
(95% CI, $36 286–$44 220), SSIs at $20 785 (95% CI, $18 902–$22 667), C. 
difficile infection at $11 285 (95% CI, $9118–$13 574), and UTI at $896 (95% 
CI, $603–$1189) (35). For the United Kingdom the costs exceed £900 million 
(36). In a systematic review of the economic burden of patient safety in the 
acute care setting Mittmann et al. found that in general hospital populations the 
cost per case of HAI ranged from $2132 to $15018 (1).  
However, all these estimates are related to direct healthcare-related costs. 
Indirect costs of HAIs such as time away from home for the person suffering 
from HAI, and if employed, absenteeism, sick leave, and potential loss of work 
and income have not been well quantified. Additionally, family members’ time 
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2.1.4. Risk factors of healthcare-associated infections 
The strongest determinants of HAI risk are the characteristics and exposures of 
patients that predispose them to infection and complex interactions of agent 
(microorganism causing infection), host (susceptible patient), and environment 
(e.g., hospital ICU, outpatient, hemodialysis center) (37). Risk factors for HAI 
can be divided into intrinsic (patient-related) and extrinsic (medical intervention 
or healthcare delivery related) (Table 1) (38). Among hospitalized populations 
admission to ICU itself is a major risk factor for development of HAI mostly 
due to widespread use of invasive devices in this department (39).  
 
 
Table 1. Most common risk factors that predispose to HAI (40, 41). 
Patient related factors Extremes of age 
Nutritional status 
Underlying medical conditions 
Severity of illness 
Suppressed immune system 
Medical intervention related 
factors 
Invasive devices (e.g., intravascular catheters, urinary 





Prolonged exposure to the health care system 
Healthcare delivery related 
factors 
 
Failure to implement basic prevention techniques 
(hand hygiene, aseptic technique) 
Environmental contamination 
Overcrowding, suboptimal nurse-to-patient ratios 
Inadequate cleaning, disinfection and sterilization of 
medical supplies and equipment 
 
 
Pediatric and adult patients share common extrinsic risk factors (37). Additional 
risk factors specific to pediatric or neonatal population include gestational age, 
gender, birth weight, congenital abnormalities, race, nutritional status, genet-
ically determined immune status, therapy, and vaccination (37). Newborns 
hospitalized in a NICU have host factors that increase their risk of acquiring 
HAI and developing more serious illness (42). One of the reasons for that is 
probably due to the differences in the function of innate and adaptive immune 
systems. Infants with birth weights less than 1500 g (very low birth weight – 
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VLBW) have rates of HAIs 3 times higher than those who weigh more than 
1500 g at birth. Moreover, besides diminished immune system function the 
likelihood of severe illnesses needing invasive monitoring and procedures 
increase susceptibility to HAI of VLBW newborns.(42) 
HAIs are rarely triggered by a single factor, but are mainly the result of mul-
tiple events that may lead to infection (43). 
 
 
2.1.5. Sources and transmission of pathogens 
Microorganisms from either endogenous or exogenous sources may cause HAI. 
Endogenous sources are body sites that are normally colonized by indigenous 
microbiota. These microbes can become invasive under certain favourable 
conditions and/or cause infection when they contaminate sterile sites. Exo-
genous sources are those external to the patient, e.g., healthcare workers, visit-
ors, patient care equipment, medical devices, or the healthcare environment.(3) 
The transmission may occur through one or more five different routes: con-
tact (either direct or indirect), droplet, airborne, common vehicle, and vector-
borne. Contact transmission is the most frequent and important mode of trans-
mission of exogenous HAI pathogens (44). Indirect contact transmission occurs 
most frequently via healthcare workers’ hands (45). The transmission of exoge-
nous organisms is also called horizontal or cross-transmission. 
It has been estimated that the source of pathogens causing HAI in the ICU 
was the patients’ endogenous flora (40–60%); cross-transmission via the hands 
of personnel (20–40%); antibiotic driven changes in microbiota (20–25%); and 
other (including contamination of the environment) (20%) (46).  
During outbreaks, the most frequent sources, described in a review of 1022 
outbreak investigations, were patients themselves (25.7%), followed by medical 
equipment or devices (11.9%), the environment (11.6%), and the staff (10.9%) (47). 
Transmission was by contact in 45.3%, by invasive technique in 16.1%, and 
through the air in 15.0%. In 37% and 28.3% of the outbreaks the authors were not 
able to identify the sources or the mode of transmission, respectively (47). 
 
 
2.1.6. Causative pathogens and antimicrobial resistance 
Bacteria, fungi, and viruses have been reported as causative agents in HAIs and 
many infections are polymicrobial (48). In contrast to the 1970s, major shifts in 
the etiology of HAIs occurred in the decades between 1980 and 2000, where 
Gram-positive and fungal infections became more common (48). However, 
recent years have seen shift in the pattern of infecting organisms towards Gram-
negative infections that are especially common and problematic in ICUs, where 
these bacteria account for about 70% of pneumonias and UTIs (49). Several 
Gram-negative organisms are responsible for HAIs, Enterobacteriaceae is the 
most commonly identified group overall (49). 
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Data from the ECDC point prevalence survey of HAI and antimicrobial use 
identified five most commonly reported HAI pathogens: E. coli (15.9% of all 
types of HAIs), S. aureus (12.3%), Enterococcus spp. (9.6%), P. aeruginosa 
(8.9%) and Klebsiella spp. (8.7%) (Table 2). The causative microorganisms 
varied depending on the type of HAI. The leading pathogens causing LRTI, 
SSI, UTI, BSI were P. aeruginosa (17.4% of all LRTIs), S. aureus (17.9% of all 




Table 2. Distribution of most commonly isolated microorganisms in HAIs by type of 













E. coli 1601 15.9 8.8 14.0 36.2 11.0 
S. aureus 1243 12.3 12.6 17.9 1.8 15.9 
Enterococcus spp. 969 9.6 2.2 14.5 12.5 8.2 
P. aeruginosa 901 8.9 17.4 7.6 8.4 6.1 
Klebsiella spp. 872 8.7 11.4 6.0 12.0 9.8 
CoNS 752 7.5 1.7 9.6 1.4 18.5 
Other 
Enterobacteriaceae 
752 7.5 6.9 7.2 13.0 5.3 
Enterobacter spp. 422 4.2 5.0 5.4 3.9 3.4 
Acinetobacter spp. 366 3.6 8.7 2.9 1.5 4.1 
Streptococcus spp. 246 2.4 2.7 3.6 0.7 2.8 
 
 
In the US point prevalence survey C. difficile was the most commonly reported 
pathogen (causing 12.1% of HAIs), followed by S. aureus (10.7%), K. pneu-
moniae or K. oxytoca (9.9%), E. coli (9.3%) and Enterococcus spp. (8.7%) (24). 
Among pediatric population pathogen distribution varies according to age 
group and setting. In contrast to adults, CoNS are the most common nosocomial 
pathogens among patients in NICUs and PICUs of developed countries ac-
counting for up to half of cases, mostly because of an increase in the improved 
survival of infants with VLBW and the high incidence of BSI (31, 50, 51). 
Gram-negative organisms are major contributors to HAI in developing countries 
(31). Although less frequent than Gram-positive or Gram-negative microorgan-
isms, Candida spp. are major pathogens among immunocompromised and 
critically ill children, including premature infants (31). Significant variation 
between centres with invasive candidiasis rates ranging from 2–20% among 
ELBW neonates have been described (52). In addition, children are at risk to 
18 
 
infections that have been prevented in older patients by vaccination or previous 
natural exposure (31). Namely, respiratory viruses, rotavirus, varicella zoster 
virus, and pertussis represent persistent challenges in children’s hospitals (31).  
The rate of antimicrobial resistance among nosocomial pathogens is in-
creasing for nearly all antimicrobial-pathogen combinations that have been 
examined, but these resistance rates differ markedly within and between coun-
tries (53). The EARS-Net collects data on resistance from invasive bacterial 
infections and its report shows general Europe-wide increase of antimicrobial 
resistance in the Gram-negative pathogens (54). Microorganisms producing 
extended spectrum beta-lactamase (ESBL) and carbapenemases have increased 
their prevalence in Europe, and in some areas are “crossing the border” from 
hospital settings to the community (55). Increasing percentages of carbapenem 
resistance in K. pneumoniae isolates were reported from progressively more 
countries in Europe between 2005 and 2010 (56). The number of countries with 
≥ 1% carbapenem resistance amongst invasive K. pneumoniae isolates increased 
from 2 in 2005 (Greece, 27.8%; Germany, 3.1%) to 5 in 2010 (Greece, 49.8%; 
Cyprus, 16.4%; Italy, 12.5%; Hungary, 5.9%; Portugal, 2.2%) (56). In 2011 
15% of P. aeruginosa isolates were reported as resistant to at least three 
antimicrobial classes (57). According to the multicentre surveillance studies the 
proportion of imipenem resistant A. baumannii strains is reported to be as high 
as 85% in bloodstream isolates from ICU patients in Greece and 48% in clinical 
isolates from hospitalized patients in Spain and Turkey (58).  
Resistance of Gram-negatives has also increased in Estonia, e.g., resistance 
of invasive K. pneumoniae to 3rd generation cephalosporins increased from 
8.1% in 2005 to 23.3% in 2013 (54). Carbapenem resistance of K. pneumoniae 
is still relatively low (5% in 2012) in Estonia, however significant inter-hospital 
variation occurs (59). Since November 2014 few sporadic carbapenemase posi-
tive Enterobacteriaceae strains have been detected (data from synlab Eesti, 
personal communication) suggesting possibility of other resistance mechanisms. 
In the surveillance study of microbial resistance of European ICUs, 13.7% of P. 
aeruginosa strains were resistant to imipenem in Estonia (60). 
Among Gram-positive microorganisms the percentage of S. aureus isolates 
reported as methicillin-resistant (MRSA) is now stabilising or decreasing in 
most European countries including Estonia where the rate was 3.5% in 2013. 
Still, the percentage of MRSA is above 25% in several countries, mainly in 
southern and eastern Europe.(54) 
Similar to the adult setting, the emergence and dissemination of antimicro-
bial resistant organisms is a crucial concern in pediatric population. Data col-
lected from 17 European hospitals in eight countries showed incidence of 
MRSA 18% and major resistance problems with ESBL-producing Enterobacte-
riaceae (26). According to the Antibiotic Resistance and Prescribing in Euro-
pean Children (ARPEC) project (focussing on blood culture isolates) MRSA 
accounted for 16% of all invasive S. aureus isolates (61). Similarly to adults the 
incidence was the highest in southern (24%) and the lowest in northern parts of 
Europe (4%) (62). Despite the rising relevance of multi drug-resistant Gram-
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negative infections in adults only a few studies have evaluated this problem in 
pediatric population (62). ARPEC project observed that 13 % of invasive E. coli 
and 33% of K. pneumoniae strains were resistant to the third generation cepha-
losporins suggesting for ESBL production (61). In the ARPEC study car-
bapenem-resistance was low – <1% of E. coli and 7% of K. pneumoniae isolates 
were resistant to carbapenem (61). 
Patients who develop infections due to antimicrobial-resistant organisms 
have significantly higher rates of morbidity and mortality, longer hospitaliza-
tions, and greater hospital costs (40). Because of the scarce antibiotic pipeline, 
the most important tools against the spread of antibiotic resistant organisms are 
intensified infection control, surveillance, and antimicrobial stewardship (63). 
 
 
2.1.7. Prevention strategies 
Every HAI has its specific prevention methods based on the risk factors. During 
the last decade major progress has been made in preventing specific types of 
HAIs (35). In a systematic review the authors estimated that as many as 65% to 
70% of CLABSIs and UTIs and 55% of VAPs and SSIs may be avoidable with 
current evidence based interventions (35, 64). Landrigan et al. estimated that 
more than 75% of identified HAIs were preventable in their retrospective 
medical record review study conducted at 10 hospitals (65). 
HAI prevention is a very complex matter and a comprehensive approach to 
this includes elements, such as surveillance, benchmarking, recommendations 
and interventions, implementation, compliance, feedback, and education.  
Surveillance is defined as “the ongoing, systematic collection, analysis, and 
interpretation of health data essential to the planning, implementation, and eval-
uation of public health practice, closely integrated with timely dissemination of 
these data to those who need to know” (66). At first an efficient surveillance 
program must be in place, by which the magnitude of the infection problem can 
be accurately examined in order to set (realistic) objectives and organize out-
come monitoring (67).  
The term benchmarking in its modern sense marks the process of making 
comparisons between organizations with the aim to identify and implement best 
practice and improve performance. Indicators that can be used in a benchmark-
ing exercise might refer to outcomes, processes (e.g., degree of adherence to 
hand-hygiene procedures), or structures (e.g., existence or absence of an infec-
tion-control committee). For prevention of HAIs the outcome measures such as 
infection rates have been emphasized traditionally. (68)  
Intervention(s) must be carefully chosen with respect of the objectives de-
fined and the available scientific evidence and must be balanced with common 
sense (67). The US Institute for Healthcare Improvement recommendations for 
reducing HAIs include to implement “care bundles”. The definition of a bundle 
is “a small, straightforward set of evidence-based practices – generally three to 
five – that, when performed collectively and reliably, have been proven to im-
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prove patient outcomes” (69). By combining the elements into a single com-
pound process, the potential for them all to be performed is increased. There-
fore, the principle of an all-or-none measure of the bundle is central to its success. 
Although care bundles have been criticised (especially VAP bundles), these are a 
popular topic and their effects have been evaluated in several studies.(70)  
The main challenge is to ensure implementation of and compliance with the 
evidence-based recommendations in practice. For example, hand hygiene is 
considered the simplest and most effective measure to prevent cross-transmis-
sion of microorganisms (31). Unfortunately, healthcare workers appear to have 
difficulties in performing hand hygiene procedures and compliance below 50% 
has been repeatedly reported (31). There are many barriers that may undermine 
the implementation of clinical recommendations, such as lack of awareness and 
familiarity with guidelines, staff attitudes and lack of agreement with the guide-
line (71). Convincing hospital personnel to adopt recommended preventive 
practices is one of the most difficult tasks of an infection control program. 
Using information on one’s own hospital to influence personnel is one of the 
most effective means to address a problem and apply the recommended tech-
niques to prevent HAIs.(66) Adequate and systematic reporting (feedback) and 
careful supervision of the process increases adherence rates with recommenda-
tions (67, 72). Educational support might be needed to optimise success rates of 
the quality improvement initiative before and during the implementation. In 
order to understand the rational of the intervention, proper information and 
instruction are necessary to achieve acceptable compliance rates.(67) Recently 
published systematic review concluded that audit and feedback generally leads 
to small but potentially important improvements in professional practice (73). 
The effectiveness of feedback may be increased in several ways. It is more 
effective when baseline performance is low, the source is a supervisor or 
colleague, it is provided more than once, delivered in both verbal and written 
formats, and it includes both explicit targets and an action plan (73). The 
German national nosocomial infection surveillance system has demonstrated a 
reduction of HAIs due to ongoing surveillance activities and appropriate 
feedback twice a year to the users in combination with reference data for HAI 
(74). All departments that achieved a reduction in infection rates were asked for 
possible explanations of this phenomenon. After they became aware of being in 
an outlier position compared to reference data, they started to reinforce existing 
guidelines and to implement new measures for HAI prevention (75). 
In addition, sufficient staff at unit level is a prerequisite for maintaining an 
acceptable standard of care (76). 
In conclusion, the prevention of HAIs will result in increased safety of pa-





2.2. Nosocomial bloodstream infections (adults, children) 
The frequency of BSI, their epidemiology, and the microorganisms have 
changed in parallel with the development of medical care, particularly with the 
emergence of an increasingly ill and immunocompromised population of 
hospitalized patients (77). 
 
 
2.2.1. Definition and classification of  
nosocomial bloodstream infection 
The terms bacteremia/fungemia and BSI are frequently used interchangeably 
and generally refer to the growth of a microorganism from a blood culture ob-
tained from a patient with clinical signs of infection and where contamination 
has been ruled out (78). 
In the last decade, as a result of the development of ambulatory alternatives 
to hospitalized healthcare, a new classification of BSIs as community-acquired, 
healthcare-associated and nosocomial has been proposed (79). The term “noso-
comial BSI” encompasses a narrower spectrum (21). It is typically defined as 
the demonstration of a recognized pathogen in the bloodstream of a patient who 
has been hospitalized for more than 48 hours. The term “laboratory-confirmed 
BSI” is used in case of a positive blood culture (19). 
BSIs are often classified as primary (no focus) or secondary when associated 
with clinical or microbiological confirmation of infection at a defined body site 
(e.g., urinary tract, surgical site, etc.). BSIs stemming from intravascular cathe-
ters are classified as primary infections (80). If the central line (CL) is the most 
likely source of the BSI, the definition is CLABSI (81). 
ECDC and US CDC definitions for BSI are similar and do not compromise 
comparability of the results (7). 
 
 
2.2.1. Incidence of nosocomial bloodstream infections 
Based on the population-based studies 113 000–134 000 episodes of nosocom-
ial BSI have been estimated to occur in North-America and over 240 000 epi-
sodes in Europe per year (82). 
On the basis of detailed longitudinal data from 14 hospitals in 3 continents 
between 1998 and 2007, Ammerlaan et al. demonstrated that incidence density 
of nosocomial BSIs increased in 12 hospitals, decreased in one hospital, and did 
not change significantly in another one, with the average incidence density of 
nosocomial BSIs per hospital ranging from 0.6 to 1.9 per 1000 patient-days (83). 
Hospital-wide multicentre surveillance data on nosocomial BSI in Europe 
have been reported from several countries, where the mean incidence densities 
were 0.6 (England), 0.7 (Belgium) and 0.8 (Finland) per 1000 patient-days and 
incidence was 8.4 per 1000 admissions in Spain (79, 84–86).  
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Incidence of nosocomial BSI varies widely among different departments 
being the highest in ICUs. Studies conducted in medical and surgical ICUs in 
high-income countries typically report cumulative incidence for ICU-acquired 
BSI of approximately 5% (39). However, hospital-wide studies reveal that up to 
51% of all nosocomial BSIs are acquired in the ICUs (85, 87, 88). In 2011 14 
countries reported data from 918 hospitals and 1088 ICUs to ECDC. On aver-
age, nosocomial BSI occurred in 3.0% of patients staying more than two days in 
the ICU with an average incidence density of 3.5 BSI episodes per 1000 patient-
days. Of those, 37% were catheter-related, 35% were secondary to another in-
fection, and 28% were of unknown origin.(57) Although CLABSI rates ob-
tained through surveillance programs have decreased in recent years, it is 
among the most common HAIs. The US National Healthcare Safety Network 
(NHSN) has reported the decrease of CLABSI incidence density steadily over 
the past 20 years from 8.1–11 per 1000 CL-days in 1990 to 1.3 per 1000 CL-
days in 2010 (89, 90). The rate of CLABSI is greater in developing countries. 
According to the International Nosocomial Infection Control Consortium net-
work data the overall rate of CLABSI per 1000 CL-days was 7.6 (30). 
Among pediatric population nosocomial BSIs are more frequent in the very 
young, with one-half occurring in children <1 years of age (91). Moreover, most 
of these infections occur in critically ill children representing significant major-
ity of HAIs in NICU and PICU (92, 93). In the study performed in London 
tertiary hospital nosocomial BSI incidence was almost 12-fold higher in the 
NICU compared to the pediatric wards (5.8 vs 0.5 per 100 discharges, respec-
tively) (94). Nosocomial BSI incidence in hospitalized neonates range from 
10% for all neonates to 50% in extremely preterm infants (50). Although more 
heterogeneous PICU population has underlying disease processes distinct from 
those in NICU, children are exposed to nosocomial BSI as well (25). Still, the 
type of PICU (e.g., surgical versus medical, referral centre or not) as well as the 
patientsʼ characteristics may account for differences in nosocomial BSI inci-
dence (95). Table 3 shows studies providing cumulative incidence of nosocom-
ial BSI (per 100 patients) and the incidence density of nosocomial BSI (per 
1000 patient-days) and CLABSI (per 1000 CL-days) in NICU and PICU. 
Similarly to adults, CLABSIs are among the most common HAIs in NICU 
and PICU. The HAI surveillance study in the USA estimated CLABSI preva-
lence at 2.4% in participating NICUs (24). The CLABSI incidence density 
among neonatal setting varies in different countries from 2.3 in the USA to 12.5 
per 1000 CL-days in Italy (96, 97). The risk of developing CLABSI in PICU is 
may be higher than that seen in adult ICU (96). The NHSN data revealed 1.4 
and 0.9 CLABSI per 1000 CL-days in PICU and medical-surgical ICU of 






Table 3. Studies using original or modified CDC definitions and reporting both cumu-
lative incidence of nosocomial BSI and incidence density of nosocomial BSI and 









































































































































































NICU neonates NR 4.3 3.3 6.5 Dritsakou 
(104) 



























9.6  9.1  8.3 Gupta 
(107) 
a includes cases with clinical sepsis (blood culture is negative); b calculated per 1000 




2.2.2. Risk factors for nosocomial bloodstream infections 
Identification of risk factors associated with nosocomial BSI is essential to im-
plement intervention programs. It has been demonstrated earlier that several 
intrinsic factors such as older age and patients with a wide range of comorbidi-
ties like immune suppression, diabetes, congestive heart failure, chronic liver 
disease, peripheral vascular diseases, renal diseases, coronary heart diseases, 
and cancer may influence the risk for acquiring nosocomial BSI in adults (39, 
108–116). Red blood cell transfusion and the use of total parenteral nutrition 
(particularly due to yeasts) has been associated with an increased risk for ICU-
acquired BSI (117, 118). The presence of hypothermia has been demonstrated 
as an important risk factor for the development of ICU-acquired BSI and 
pneumonia (119). Although the use of invasive devices, such as CLs and 
arterial catheters, allows for the provision of life-saving therapies and other 
important medical care, these devices also introduce risks of both infectious and 
noninfectious complications (40). Because most device-associated BSIs have 
been attributed to CLs, arterial catheterization may be an under-recognized 
source (39, 120–122). In recent systematic review the rate seen in the systemati-
cally cultured arterial catheters (1.6 BSIs per 1000 arterial catheter days) was 
similar to what has been reported for BSIs associated with short-term CLs 
(122).  
In pediatric population the birth weight and gestational age are the most im-
portant risk factors of nosocomial BSI (93). In a cohort of infants admitted to 
250 NICUs in the US, there were 374 infections for every 1000 admissions for 
infants <750 g birth weight and only 7 infections per 1000 admissions in infants 
>2500 g birth weight (123). In a recent study, 36% of 9575 extremely low-
gestational-age infants (22 to 28 weeks) developed nosocomial BSI (124). Fur-
thermore, the lower the birth weight or gestational age, the more invasive tech-
nology is used (42). Perlman et al. analyzed a large cohort of 2935 of neonates 
and found that significantly more babies with nosocomial BSI weighed < 1000 
g as compared with neonates who did not develop nosocomial BSI (50.7% and 
8.1%, respectively) and had a CL (88.8% vs 34.8%, respectively) (125). Both 
adults and children with CL share common risk factors for CLABSI such as 
underlying disease, length of ICU stay prior to CL insertion, prolonged in-
dwelling time of CL (from more than 6 days up to more than 15 days), number 
of CL lumens, exchange of CL over a guide wire, insertion site, total parenteral 
nutrition, receipt of blood transfusion, presence of gastrostomy tube and 









2.2.3. Spectrum of pathogens causing  
nosocomial bloodstream infections 
The microbial profile of nosocomial BSI has changed considerably over the past 
several decades in response to changes in patient population, antibiotic use, 
more intensive medical care and prevention methods (80). 
In the two largest hospital-wide multicentre studies of nosocomial BSI in 
adults and children performed between 1995–2007 in the Americas and Europe, 
Gram-positive bacteria caused 44%–65%, Gram-negative organisms 25%–37%, 
anaerobes 3% and fungi 5%–10% of the infections (83, 87). In SCOPE project 
CoNS and S. aureus were the most commonly isolated organisms both in the 
ICU and the non-ICU settings, followed by Candida spp. and Enterococcus spp. 
(87). P. aeruginosa and E. coli were the fifth most frequent isolates in ICU and 
non-ICU settings, respectively (87). Hospital-wide surveillance data from 14 
hospitals not including possible contaminants like CoNS revealed Entero-
bacteriaceae (22.6%), S. aureus (11.4%) and enterococci (8.0%) as the most 
frequent pathogens (83). Table 4 displays the distribution of organisms from 
multicentre studies investigating the epidemiology of nosocomial BSIs. The 
most important change in the epidemiology of BSI in recent years is the 
emergence of highly resistant organisms, particularly with extensively resistant 
Gram-negative bacteria including P. aeruginosa, A. baumannii, and Entero-
bacteriaceae (39). 
During the past two decades, the incidence of candidemia has been increased 
in North American and European studies (133–135). A shift towards more fre-
quent isolation of non-albicans Candida species with reduced susceptibility to 
azole antifungal agents has been a global concern (136). 
The profile of pathogens associated with CLABSI has also changed consid-
erably during the past decade. A summary of CLABSIs reported by NHSN 
found that S. aureus CLABSI incidence density rate has fallen below those of 
Candida spp., enterococci, and Gram-negative bacteria among adults (89). 
These changes probably reflect the success of CLABSI prevention measures 
(89). Still, the most common pathogens associated with CLABSI both in chil-
dren and adults are CoNS (137). On the other hand, as CoNS are abundant colo-
nizers of the skin, they frequently contaminate blood culture samples, leading to 
false positive results (138). Contaminated blood cultures can have a deleterious 
effect on patient care; they may lead to longer hospital stays, unnecessary anti-
biotic therapy, needless removal of CLs, and redundant laboratory testing (138). 
In several studies among adults and children the contamination rate has been 
decreased (from 3.7%–6.7% during the preintervention period to 1.6%–2.3% 
during the postintervention period) by using education and protocols to stand-
ardize the process of obtaining a blood culture specimen (138–140). The use of 
phlebotomy teams has found to be effective practices for reducing blood culture 
































































































































































































































































































































































































































































































































































































2.2.4. Outcome of nosocomial bloodstream infections 
The overall case-fatality rate of nosocomial BSIs varies in published hospital-
wide surveillance reports from 12 to 32% (82). In the Eurobact cohort study that 
involved 1156 patients with nosocomial BSI in 165 ICUs from 24 countries, the 
28-day BSI mortality was 36% (116). 
Mortality associated with nosocomial BSI is multifactorial. The final 
outcome is influenced by the source of infection, etiology, age, underlying 
disease, acute illness, and appropriateness of antimicrobial treatment. Therefore, 
estimates of mortality attributable to nosocomial BSI may differ largely 
according to the presence or absence of risk factors in distinct patient popu-
lations (144). For example, whereas nosocomial BSI has estimated attributable 
mortality 3% in pediatric patients, the estimate is 11% among neonates with 
VLBW (50). In addition to high mortality, neonatal BSI is associated with 
adverse neurodevelopmental outcome (145). In adult population, the attribu-
table mortality to nosocomial BSI varies in different studies accounting for 12% 
in neutropenic (146), 16% in older (147), 25–35% in ICU patients (114, 148). 
The Charlson comorbidity index (CCI), which is based on the International 
Classification of Diseases (ICD)-10 codes, has been well validated for pre-
dicting mortality in patients with bacteremia (149). The CCI attributes a score 
varing from 0 to 6 to 17 diseases that have been shown to be associated with 
higher mortality (149). A total score is calculated from the sum of the weighted 
scores. This score is an indicator of disease burden and a strong estimator of 
mortality (150).  
The microorganisms responsible for nosocomial BSI possess different viru-
lence factors that may have direct impact on prognosis (151). It may be compli-
cated to demonstrate a direct relationship between species and prognosis in 
ICUs independent of predisposition characteristics, inflammatory response, and 
organ dysfunction (39). However, in a large multicentre ICU study the adjusted 
OR for hospital death of ICU-acquired BSI compared to matched patients with-
out BSI was minimal and nonsignificant for CoNS, 2 for other Gram-positive 
cocci, 6 for Gram-negative bacilli, and 9 for Candida spp. (114). Many studies 
have found that bacterial resistance decreased the chance of early adequate 
therapy contributing to the mortality increase (116, 152). In a recent review BSI 
caused by ESBL or carbapenem-resistant K. pneumoniae and delay in admin-
istration of appropriate therapy were among the most common risk factors for 
mortality in patients with K. pneumoniae BSI, while infection source control 
and early appropriate antimicrobial treatment were associated with increased 
survival (153). The abdominal and pulmonary sources of infections are usually 
contributing to the poorer outcome, whereas CLABSIs have better prognosis 
(39, 113, 114). However, important consequences of CLABSI may include 
extended hospital stay (median attributable length of stay from 7 to 18 days), 
interruption of chemotherapy or other treatment, catheter removal, intravascular 
thrombosis and endocarditis (154, 155). Furthermore, BSI including CLABSI is 
associated with increased hospital costs (155, 156).  
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In general, among HAIs nosocomial BSI carries the highest mortality, it is 
associated with increased short- and long term costs and neonates represent the 
age-group at highest risk for poor outcome. 
 
 
2.2.5. Prevention of nosocomial bloodstream infections 
The prevention of nosocomial BSI requires prevention of CLABSI and other 
sites of infection (pneumonia, UTI, SSI etc) as sources for secondary bactere-
mia (80). During the last decade much effort has been dedicated to prevent 
CLABSI – the most common BSI in acute care setting (157). Initial efforts 
focused on evidence based practices at the time of CL insertion. Subsequent 
studies have evaluated novel technologies to reduce CLABSI including anti-
biotic or antiseptic-coated catheters, needleless devices, antiseptic dressings, 
and chlorhexidine body wash (158, 159). Thus, prevention efforts have broad-
ened beyond insertion practices to include evidence-based practices for appro-
priate maintenance of CLs (159). Policies and protocols or ‘bundles’ dictating 
catheter insertion and management have been demonstrated to reduce CLABSI 
(157, 160). The Michigan bundle (appropriate hand hygiene, use of chlorhexi-
dine-containing products for skin preparation, use of maximal barrier precau-
tions during CL insertion, subclavian vein placement as the preferred site, and 
removing unnecessary CLs) is considered minimal practice standard today (90, 
157).  
Unique considerations are involved in the prevention of CLABSI in pediatric 
patients (29). Difficult intravenous access often requires insertion of catheters in 
sites that have higher infection rates. Additionally, catheters need to be main-
tained for prolonged time because of difficult vascular access and the need to 
obtain blood. Maintenance practices must be altered depending on the maturity 
of an infant’s skin.(29) Chlorhexidine bathing has been successfully tested in 
PICUs and NICUs (161, 162). However, in VLBW infants, chlorhexidine may 
cause chemical dermatitis or burn, and chlorhexidine-impregnated biopatches 
may cause pressure ulcers (29, 163, 164). Antibiotic-impregnated catheters, 
antibiotic and antiseptic locks have been examined in pediatric oncology pa-
tients and in children on hemodialysis (96). A systematic review failed to detect 
a benefit of antibiotic-based lock solutions in CLABSI reduction among those 
patients (165). The availability of impregnated catheters for small children is 
limited (96). 
The CLABSI prevention strategies described in adult ICUs have also been 
successfully tested in neonatal and pediatric ICU populations. In 2007 18 
NICUs in New York State adopted common CL insertion and CL maintenance 
practices, followed by a 67% statewide decline in CLABSI rates (6.4 versus 2.1 
per 1000 CL-days) (166). A large prospective surveillance study including nine 
PICUs and 1986 patients in developing countries compared CLABSI rates be-
fore and after implementation of an infection control program, which included 
education, evidence based practices, surveillance, and feedback of data to pa-
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tient care units. Although there were significantly more CL-days in the post-
implementation group, the CLABSI rate was reduced by 52% (167). 
In addition, the importance of adequate staffing in ICUs and its relationship 
to CLABSIs has been reported (168–170). The structured training of medical 
trainees can lower risk for CLABSI (171).  
For years, almost all CLABSI surveillance efforts and prevention studies 
have been limited to the ICU setting, but one-third or more of all CL-days may 
occur outside of the ICU (172). CLs are also used in patients who primarily 
receive their care as outpatients, including those requiring hemodialysis or 
chemotherapy, and receiving parenteral nutrition (173). Recently, the need for 
strategies for preventing CLABSI outside the ICU has been emphasized (131). 
In the Spanish non-ICU study where the intervention consisted of: 1) evidence-
based bundle of practices relating to catheter insertion and maintenance; 2) a 
training program for healthcare workers; 3) four point–prevalence surveys to 
track the status of the catheters; and 4) feedback reports to the staff involved, 
the incidence density of CLABSI significantly decreased from 0.14 to 0.10 per 
1000 patient-day (174). Infection prevention measures targeting the post-inser-
tion time of CLs and maintenance practice are more likely to be successful in 
non-ICU settings (175). 
 
 
2.3. Surgical site infections 
2.3.1. Definition and classification of surgical site infection 
The CDC term for infections associated with surgical procedures was changed 
from surgical wound infection to SSI in 1992 (176). SSIs are classified as being 
either incisional or organ/space. Incisional SSIs are further divided into those 
involving only skin and subcutaneous tissue (superficial incisional SSI) and 
those involving deeper soft tissues of the incision (deep incisional SSI). Or-
gan/space SSIs involve any part of the anatomy (e.g., organ or space) other than 
incised body wall layers, that was opened or manipulated during an opera-
tion.(14) Diagnosis is based on signs and symptoms, hence SSIs cannot be relia-
bly identified from laboratory data alone (177). Detailed criteria for these 
definitions have been described in Table 10. 
SSI rates vary according to co-morbidities and to the contamination class 
and conditions of the surgical procedure. The need for adjustment has been 
demonstrated and most surveillance networks use the NHSN (previously Na-
tional Nosocomial Infections Surveillance NNIS) System index for risk strati-
fication (178). The NHSN System risk index is operation-specific and applied 
to prospectively collected surveillance data. The index comprises 3 dichoto-
mous variables: American Society of Anesthesiologists (ASA) score (3, 4, or 5), 
wound classification (contaminated or dirty), and procedure duration in minutes 
(>75th percentile). Each risk factor represents 1 point; thus, the NHSN SSI risk 
index ranges from 0 (lowest risk) to 3 (greatest risk).(14, 20) More complex 
systems of risk adjustment have been recommended for some types of surgery 
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like CS, coronary arter bypass graft or general and vascular surgery (179–181). 
Development of more refined methods of case-mix adjustment of SSI is ongo-
ing by the NHSN (20). However, any form of risk index stratification is depend-
ent on data being available for all variables and practical problems emerge when 
incomplete data is captured as part of a surveillance program (182). 
 
 
2.3.2. Incidence of surgical site infections following cesarean section 
CS is the most common major surgical procedure performed on women. De-
spite the World Health Organization’s estimate that CS rates should not be 
>15%, in the developed world, CS rates are already above 20%. The CS rate 
increased by 50% in the USA between 1996 and 2006, comprising 31% of 
births or 1.3 million procedures annually, which could reach 50% (or two mil-
lion CSs each year) by 2020.(183) The proportion of CS births in England has 
risen substantially over the past 30 years from 9% in 1980 to 25% in 2009/10 
(184). In Estonia the proportion has increased from 6.4% in 1992 to 19.7% in 
2013 (185). 
A number of sources exist for postoperative infectious morbidity following 
CS such as UTI, pneumonia, mastitis, septic pelvic thrombophlebitis, but SSI 
(including both incisional infection and endometritis) is the leading cause (179). 
Among hospitals reporting to ECDC and NHSN, the rate of SSI after CS was 
2.8% to 5.5% and 1.46% to 3.82% depending on the risk index (0 to 3), respec-
tively (186). These rates are mostly reported for women during their inpatient 
stay. The global trend towards reducing length of hospital stay post-surgery 
means that SSI will increasingly occur after hospital discharge (15). Postdis-
charge surveillance has been described as a possibility to assess SSI, which 
were missed by in-hospital surveillance systems and to obtain accurate rates of 
SSI. Therefore, even higher rates have been calculated in single observation 
studies where postdischarge survey has been used, ranging from 4.9% in Ireland 
to 23.5% in Brazil (Table 5) (187). However, the best way to conduct postdis-















Table 5. SSI rates following CS in studies with postdischarge surveillance and using 
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4107 9.8 0.5 94.8 (188) 
Denmark 
2007–2008 
1513 7.1 3.1 56.5 (189) 
Norway 
2005–2007 
3900 8.0 1.2 85.6 (190) 
England 
2003–2005 
5563 8.8 1.4 84.0 (191) 




















187 23.5 1.1 95.5 (187) 
Norway 
2003 
326 8.9 1.8 79.3 (193) 
Scotland 
2002–2003 
715 11.2 3.1 72.5 (194) 
Australia 
1999 
247 17.0 2.8 83.3 (195) 
US  
1996–1998  
765 7.7 5.0 35.6 (196) 
 
 
2.3.3. Risk factors for surgical site infection  
following cesarean section 
The single most important risk factor for postpartum maternal infection is deliv-
ery by CS (197). Maternal morbidity related to infections has been shown to be 
5-fold to 20-fold higher after CS compared to vaginal delivery, though this 
varies according to definition, classification and duration of observation (183, 
198). 
Various patient- and procedure-related factors affect infection rates in differ-




2.3.3.1. Patient-related factors 
Obesity as a risk of postcesarean SSI has been known for years. Tran et al. 
identified obesity as an independent risk factor for SSI, with the odds ratio in-
creasing 2.0 for every 5 unit increment in body mass index (BMI) (95% CI, 1.3–
3.0) (199). Gong et al. found that obesity had an OR of 4.5 (95% CI, 1.5–12.9) 
(200). Possible biological explanations for this association include the relative 
avascularity of adipose tissue, the increase in wound area, and poor penetration 
of prophylactic antibiotics in adipose tissue (201). Higher BMI has also been 
shown to be associated with lower diet quality during pregnancy. A variety of 
micronutrients play critical roles in immune responses, so it is plausible that 
micronutrient deficiencies associated with poor diet could be associated with 
increased risk of endometritis in women with low socioeconomic status (202). 
The increased risk of infection following a CS in hypertensive women may 
be explained by the chronic alteration in peripheral blood supply as a result of 
increased vascular resistance (203). 
Younger age has been reported to be associated with an increased risk of SSI 
after CS in several studies. Olsen et al. found that younger women had signifi-
cantly fewer prenatal visits than older women and therefore probably less op-
portunity for diagnostic testing, for example for sexually transmitted infections 
(202). Remote infection can increase the inoculum of microorganisms contami-
nating the surgical site (199). 
 
 
2.3.3.2. Procedure-related factors 
An obstetric-related risk factor is the length of time that the membranes are 
ruptured prior to CS (194). Prolonged rupture of membranes increases the 
likelihood of an infection ascending from vagina into uterine cavity. 
Chorioamnionitis is closely related to prolonged rupture of membranes and is a 
risk factor for SSI (199). 
Excessive intraoperative blood loss is usually associated with poor control 
of bleeding, increased tissue damage from prolonged retraction and manip-
ulation, and more sutures (199). Sutures may promote surgical site contamin-
ation (199). The wound closure and suturing technique is a matter of personal 
choice, each surgeon developing a preference for one method over another 
(194). Some studies, including recently published randomized controlled 
clinical trial, have identified a higher risk of SSI associated with closure using 
staples (194, 201, 204). 
Absence of the antibiotic prophylaxis is the risk factor for SSI following CS 
(196). Perioperative antibiotic prophylaxis (PAP) for women undergoing CS 
has been proven to be beneficial in decreasing postcesarean infectious morbid-
ity both in women at high-risk (in labour after membrane rupture), or low-risk 
(non-labouring with intact membranes) (183). A single dose perioperative of 
antibiotics is as effective as multiple doses, and the routine use of prophylactic 
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antibiotics reduces the risk of infection by more than 50% (183). This will be 
discussed in detail under “Prevention of SSI following CS.” 
 
 
Table 6. Risk factors associated with surgical site infections following cesarean section. 
Patient-related risk 
factors 
References Procedure-related risk 
factors 
References 
Younger age (184, 191, 202) Absence of antibiotic 
prophylaxis 
(196, 200) 
BMI category > 24 or 
obesity 
(184, 191, 193, 
194, 200, 201, 
205, 206) 
Blood loss (191, 199) 
ASA score  3 (199) Emergency CS (191, 195, 198, 
207) 
Diabetes (207) Wound closure with 
staples 
(191, 194, 201, 
204) 
Hypertension (187, 207) Surgery time (longer 
duration of operation) 
(193, 196, 200, 
206) 
Premature rupture of 
membranes 
(196, 200, 207) Development of 
subcutaneous hematoma 
after the procedure 
(201) 
< 7 prenatal 
consultations 
(196) Operation performed by 





(199, 208) Staff and Assistant 
Specialist grade surgeon 
(184) 
Chorioamnionitis (199) Absence of suture closure 
of subcutaneous tissue 
thickness of 2 cm 
(209) 
Preeclampsia (199) Amniotomy (202) 





2.3.4. Spectrum of pathogens causing surgical site  
infections following cesarean section 
Pathogens that cause SSI may derive from the patient’s own microbial flora on 
the skin and in the body, or from the skin or mucous membranes of operating 
personnel, or from the operating room environment (including air), and less 
frequently from the instruments and tools used during the procedure (182). In 
the multicentre cohort study performed in England causative microorganisms 
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were recorded for 39.8% of the SSI following CS (157/394). Of these infections 
24.2% were reported to be polymicrobial. The most commonly reported patho-
gen was S. aureus (40.4%) of which 17.1% were methicillin-resistant. Other 
pathogens included anaerobic cocci (23.2%), Enterobacteriaceae (13.3%) and 
streptococci (7.4%).(184) The most common pathogens causing obstetric/ 
gynecologic surgery SSIs reported to the NHSN during the years 2009–2010 
were S. aureus (19.7%), enterococci (13.6%), E. coli (12.9%), and CoNS 
(8.9%) (211). In Germany the most frequent pathogens causing SSI following 
CS were S. aureus (129 infections), enterococci (45), streptococci (42) and  
E. coli (29). In 60% of all SSIs no pathogen was reported (75). In summary, the 
reported causative organisms of postcesarean SSI are usually common skin or 
female genital tract microbiota.  
 
 
2.3.5. Outcome of surgical site infections following cesarean section 
Although most SSIs following CS are superficial, this represents a substantial 
burden to the healthcare system given the high number of women undergoing 
this type of surgery. Superficial SSIs are likely to result in pain and discomfort, 
require antimicrobial therapy and may progress to affect deeper tissues. The 
more severe infections involving deeper tissue or reproductive organs (e.g., 
endometritis) necessitate extended hospital stays or readmission to hospi-
tal.(184) The median postcesarean length of hospital stay has been 3 days in 
recent studies (188, 191). The crude increases in length of hospital stay (begin-
ning with the date of CS and including length of stay during hospital readmis-
sions that began within 30 days after CS) have been reported 2.2 days for super-
ficial and deep SSI and 1.8 days for endometritis (212). Of the 4107 women 
followed up in the study in England, 0.6% (5.9% of those with SSI) were read-
mitted to hospital for treatment of their infection (184). In the study performed 
in Ireland 1.2% of 765 women with CS were readmitted due to endometritis 
(192).  
SSI is also responsible for substantial increase in healthcare-related costs 
(213). In many studies attributable costs were calculated for SSI that occurred 
after a variety of different operations, rather than calculated for post-cesarean 
SSI (212). Olsen et al. found that the attributable costs of SSI after low trans-
verse CS were approximately $3500–4000 and the majority of excess costs 
were associated with room and board and pharmacy costs (212). In the study by 
Mugford et al. SSI added £716 and 76% of these excess costs resulted from 
staffing due to longer length of hospital stay in patients with infection (214). 
For most pregnant women SSI is not life threatening, but on very rare occa-
sions the development of an infection after CS can lead to devastating outcomes 
as documented in the 2006–2008 Confidential Enquiry into Maternal Deaths 
(184). A population-based case-control study performed in France revealed that 
the risk of postpartum maternal death was 3.6 times higher after CS than after 
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vaginal delivery from complications of anesthesia, puerperal infection, and 
venous thromboembolism (215). 
Aside from short-term complications women undergoing CS, are at 
increased risk for a variety of long-term complications including pain, surgical 
adhesions (SSI may increase that risk), and infertility or subfertility. Adhesion 
formation contributes to the risk of complications at future deliveries such as 
uterine rupture, abnormal placentation and increased risk of hemorrhage leading 
to hysterectomy. All of these potential short and long-term maternal and fetal 
complications must be considered by physicians and patients when considering 
either elective primary or repeat CS.(216) 
 
 
2.3.6. Prevention of surgical site infections following cesarean section 
Approaches to the prevention and control of SSI have evolved over many years 
and traditionally have been classified into those interventions before surgery, 
during surgery and after surgery (12). General prevention methods of SSI are 
presented in Table 7.  
Among prevention methods specific for postcesarean SSI probably the most 
important is administering antibiotic prophylaxis prior to incision, rather than 
after cord clamping (217, 218). Until recently, the practice in CS was the 
administration of antibiotics after cord clamping because of the concern re-
garding possible adverse effects on the neonate (219). Recent studies have 
shown a decrease in SSI following CS when antibiotics are given pre-incision. 
A systematic review identified that antibiotic prophylaxis administered prior to 
the incision decreased the overall incidence of SSI following CS. Moreover it 
did not increase the likelihood of neonatal infection, frequency of evaluations 
for neonatal sepsis, or the duration of neonatal hospitalization. The authors 
concluded that administration of antibiotics within 30 to 60 minutes prior to 
incision seems to be optimal in order to maximize tissue and blood concent-
rations at the surgical site. (179, 220) In hospitals in Australia and New Zealand 
SSI rates dropped from 10.8% in 2010 to 2.8% in 2011 with no adverse 
neonatal consequences, providing further evidence that antibiotic prophylaxis 
should be given pre-incision for CS (219). Prophylactic antibiotic regimens 
comparing single-dose antibiotics with extended spectrum coverage have been 
evaluated in randomized controlled trials that did not demonstrate improved 
outcomes compared with standard cephalosporin prophylaxis (218). Methods 
such as surgical safety checklists are a more formal way to ensure that antibiot-
ics are administered prior to incision (221). In a Cochrane review of 5 trials 
(1946 women), vaginal cleansing with a povidone-iodine solution immediately 
before CS significantly reduced the incidence of postcesarean endometritis 
(7.2–3.6%; RR, 0.39; 95% CI, 0.16–0.97) (222). Doctors and midwives can also 
be directly responsible for other infection prevention strategies such as 
instructing women to not remove pubic hair before the expected date of CS and 
wound management education (223).  
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Several prevention methods are directly related to surgical technique. In re-
cent systematic review recommendations with high levels of certainty as de-
fined by the US Preventive Services Task Force favored cephalad-caudad blunt 
uterine extension, spontaneous placental removal, surgeon preference on uterine 
exteriorization, single-layer uterine closure when future fertility is undesired, 
and suture closure of the subcutaneous tissue when thickness is 2 cm or greater 
(218). 
Although preventing all SSIs may not be feasible, guidelines of peri- and 
postoperative measures have been developed to minimise the risk of SSI (178). 
SSI surveillance is a component of these guidelines (14). Avoiding more severe 
infections is a priority, but monitoring superficial as well as deep infections 
provides a higher sensitivity with which to examine the quality of care and de-
tect potential problems with infection prevention (184). 
 
 
Table 7. Major interventions in preventing surgical site infection from UK and North 
American guidelines (12, 14, 225). 
Preoperative phase  Patient showering  
Proper hair removal  
Patient and staff jewellery removal 
Patient and staff theatre wear  
Movement to and from theatre area  
Controlling blood glucose 
S. aureus nasal decontamination  
Mechanical bowel preparation (not routine)  
Perioperative antibiotic prophylaxis  
Intraoperative phase Hand hygiene  
Surgical attire (gowns, gloves) 
Antiseptic skin preparation  
Diathermy 
Patient homeostasis (oxygenation, normothermia, etc.) 
Operative technique 
Draping 
Wound irrigation and dressings 
Postoperative phase Maintaining normothermia after colorectal surgery  
Dressings 
Postoperative cleansing of surgical site 
Topical agents (not indicated) 
Antibiotic treatment and debridement for SSI 





3. STUDY RATIONALE 
Registration of HAI has become mandatory in EU since 2009 focussing on 
ICU-acquired infections and SSI. There is evidence to support the use of post-
discharge SSI surveillance; however, consensus on the ideal method has yet to 
be met (14, 182). Some information on postdischarge methods has been col-
lected in the ECDC surveillance of SSI since 2010, but these data have not been 
provided by all countries so far (16). The ECDC also requested that all member 
states carry out a point prevalence survey of HAIs and antimicrobial use using a 
standardized protocol (4). Four hospitals from Estonia (2 regionals and 2 central 
hospitals) participated in European point prevalence survey of HAIs and anti-
microbial use in 2011. This study revealed that 5.7% of patients had at least one 
HAI on the day of the survey (4). Still, incidence surveys, and not only in ICU, 
are much better for detecting and describing related risk factors, but are more 
difficult to perform and more expensive (9). Hospital-wide nosocomial BSI 
surveillance may have some advantages compared to other HAIs (10). 
The research presented in current thesis started in 2002. Before that only few 
studies had investigated hospital-acquired microorganisms in Estonia. Karki et 
al. compared the susceptibility patterns of S. aureus and E. coli isolated from 
patients with hospital-acquired and outpatient infections (18). Siiri Kõljalg de-
fended PhD thesis in 1999 and her work concentrated on nosocomial pathogen 
Acinetobacter spp. However, no study of the epidemiology of HAI had been 
performed and there was no surveillance system of HAI in Estonia during this 
time. To fill the gaps we chose to investigate SSI following SC, one of the most 
frequent surgical procedure worldwide (216, 224), and nosocomial BSI as the 




4. AIMS OF THE STUDY 
The general aim of the present thesis was to assess the epidemiology of HAI 
among adult and pediatric patients in Estonia in order to promote HAI surveil-
lance at hospital level and to create knowledge and experience base for preven-
tion activities in the future.  
The specific aims were the following: 
1. To measure the incidence and outcome of nosocomial BSI in three  
major hospitals. 
2. To analyse most frequent potential factors predisposing patients to 
nosocomial BSI and to find out the risk areas (wards). 
3. To identify the spectrum of pathogens causing nosocomial BSI in and 
to study their antimicrobial resistance. 
4. To identify the incidence and risk factors associated with SSIs follow-
ing CS in Tartu University Hospital. 
5. To evaluate a multimethod approach to postdischarge surveillance of 
SSIs following CS. 
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5. PATIENTS AND METHODS 
A summary of the patients and methods included into three studies of the thesis 
is presented in Table 8. 
 
 
Table 8. Overview of the study subjects, designs and identified healthcare-associated 
infections in studies I–III. 
Study Study design and 
location 
Time period Study subjects Type of HAI  
I Prospective hospital-
wide surveillance in the 
North Estonia Medical 
Centre, Tartu University 
Hospital and East-














II Prospective surveillance 






All patients aged 





acquired BSIs  
III Cross-sectional survey 
in Women’s Clinic of 
Tartu University 
Hospital 









a Nineteen months in the North Estonia Medical Centre 
 
 
5.1. Setting of the studies 
Two referral centers (The North Estonia Medical Centre and Tartu University 
Hospital) providing tertiary care for the entire Estonian population and one 
central hospital (East-Tallinn Central Hospital) participated in the study I 
(Table 8).  
East-Tallinn Central Hospital is serving approximately a population of  
200 000. The hospital provides care in different clinics (Internal Medicine, Eye, 
Surgery, Medical Rehabilitation, Long-Term Nursing, Diagnostic and Women`s 
Clinic). Around 25 000 patients were hospitalized annually during the study 
years. In 2004 there were 588 beds including 9 in the third level ICU.  
The North Estonia Medical Centre is the tertiary care referral hospital that 
offers medical care in all specialities except ophthalmology, pediatrics and ob-
stetrics. Each year around 40 000 patients are admitted to the hospital serving 
primarily North Estonia. In 2004 there were 1236 beds including 42 in the third 
level ICU.  
Tartu University Hospital is a referral teaching hospital with approxi-
mately 43 000 admissions annually serving primarily the population in South 
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and North-East Estonia (about 600 000 people including 5000 births per year, 
2004 data) (226). Bone marrow and organ transplantations and congenital heart 
disease surgeries are performed. About 16% of all patients treated at Tartu Uni-
versity Hospital are children. In 2004 there were 944 beds including 43 in the 
third level ICU.  
Study II was performed at Tartu University Hospital in PICU (level III) 
with nine beds having annually approximately 250 admissions of which 50–
60% are neonates. In this mixed PICU the patient population ranges from 
ELBW neonates to adolescents comprising a wide variety of conditions includ-
ing congenital malformations requiring surgical repair; pediatric emergencies 
including multiple trauma, near-drowning or poisonings; infectious diseases and 
neonatal conditions. Patients are admitted from home, transferred within the 
hospital (including from hematology, cardiac surgery and maternity unit) or 
from district hospitals. In case of suspected early onset neonatal sepsis gentami-
cin with ampicillin in VLBW or with penicillin G in other neonates is used. In 
infants and children cefotaxime with gentamicin is the preferred empiric ther-
apy for sepsis. Fluconazole prophylaxis is administered to ELBW neonates. 
Risk factor based intrapartum prophylaxis with penicillin G for the prevention 
of perinatal group B streptococcal disease is employed. 
Women’s Clinic of Tartu University Hospital, the setting of study III, had 
54-beds and there were 2092 deliveries performed in this obstetric and gynecol-
ogy center in 2002. The number of total CS performed in 2002 was 310. During 
study period hospital policy for PAP recommended intravenous administration 
of 1 g of cefazolin as soon as the umbilical cord was clamped for all patients 
undergoing non-elective CS and for patients undergoing elective CS for rupture 
of membranes more than 4 hours or with bacterial vaginosis diagnosed during 
pregnancy.  
Infection control activities were started in 2001–2002 at all three hospitals.  
 
 
5.2. Subjects of the studies 
Data on patients included in the studies are presented in Table 8. 
All acute care patients meeting definition of nosocomial BSI were included 
in the hospital-wide surveillance study. The patients admitted to the depart-
ments of long-term nursing, psychiatry and tuberculosis were excluded because 
of the low risk of HAI in these departments. 
The PICU study population consisted of all children with ICU-acquired BSI.  
In the surveillance study of SSI following CS the population consisted of all 
women who delivered by elective and emergency CS during the study period. 
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5.3. Definitions used in studies 
Episode of BSI – isolation of bacteria/fungi from at least one blood culture set 
(see Table 9) (19) or repeatedly positive cultures with phenotypically similar 
microorganism within a 7 days period  
Nosocomial BSI – bacteremia/fungemia occurring more than 48 h after ad-
mission, or resulting from earlier hospitalization within previous 30 days 
ICU-acquired BSI – bacteremia/fungemia developing after 48 h of admission 
to ICU  
Primary BSI – bacteremia/fungemia resulting from intravenous or arterial 
catheter infections and bacteremia/fungemia with unknown origin  
CLABSI – primary BSI developing in a patient that had a CL within the 48 
hours prior to the infection onset 
Secondary BSI – bacteremia/fungemia secondary to infection with the same 
microorganism at a distant body site or with clinical suspicion without isolation 
of a microorganism  
Polymicrobial BSI – isolation of different species from one or more blood 
cultures within 48 h 
Probable blood culture contaminant – skin commensals (CoNS, Micrococcus 
sp., Bacillus sp., Propionibacterium sp.,or Corynebacterium sp.) that do not 
correspond to the BSI definitions for common skin contaminants presented in 
Table 9  
Blood culture set – culture of blood obtained from a single venipuncture and 
inoculated into one or multiple bottles 
Appropriate antimicrobial treatment – the patient received at least one 
antimicrobial agent that was active against the implicated pathogen in vitro on 
the day of sampling 
Neonate – term and preterm baby (≤ 33 gestational weeks) up to 28 and 90 days 
of age, respectively 
SSI – infection occuring after surgery in the part of the body where the surgery 
took place (see Table 10) (14)  
Surgical wound classification for CS (according to the modified surgical 
wound classification by Tran et al. (199) 
class I (clean) – no rupture of membranes or labor 
class II (clean-contaminated) – less than 2 hours of membrane rupture without 
labor or labor of any length with intact membranes 
class III (contaminated) – rupture of membranes greater than 2 hours 
class IV (dirty) – purulent amniotic fluid 
Elective CS – planned procedure and performed when scheduled  





Table 9. The Centers for Disease Control and Prevention definition of laboratory-con-
firmed primary BSI used in our study (19). 
Laboratory-confirmed bloodstream infection must meet at least one of the 
following criteria 
Criterion 1 Patient has a recognized pathogen cultured from one or more blood 
cultures  
and  
organism cultured from blood is not related to an infection at another 
site. 
Criterion 2 Patient has at least one of the following signs or symptoms: fever 
(>38°C), chills, or hypotension 
and 
at least one of the following: 
a. Common skin contaminant (e.g., diphtheroids, Bacillus sp., 
Propionibacterium sp., coagulase- negative staphylococci, or 
micrococci) is cultured from two or more blood cultures drawn on 
separate occasions 
b. Common skin contaminant (e.g., diphtheroids, Bacillus sp., 
Propionibacterium sp., coagulase-negative staphylococci, or micrococci) 
is cultured from at least one blood culture from a patient with an 
intravascular line, and the physician institutes appropriate antimicrobial 
therapy 
and 
signs and symptoms and positive laboratory results are not related to an 
infection at another site 
Criterion 3 Patient ≤1 year of age has at least one of the following signs or 
symptoms: fever (>38°C), hypothermia (<37C°), apnea, or bradycardia 
and 
at least one of the following: 
a. Common skin contaminant (e.g., diphtheroids, Bacillus sp., 
Propionibacterium sp., coagulase-negative staphylococci, or micrococci) 
is cultured from two or more blood cultures drawn on separate occasions 
b. Common skin contaminant (e.g., diphtheroids, Bacillus sp., 
Propionibacterium sp., coagulase-negative staphylococci, or micrococci) 
is cultured from at least one blood culture from a patient with an 
intravascular line, and physician institutes appropriate antimicrobial 
therapya 
and 
signs and symptoms and positive laboratory results are not related to an 
infection at another site. 




Table 10. The CDC definition of SSI (14) 
A superficial SSI 
Infection occurs within 30 days after the operative procedure 
and 
involves only skin and subcutaneous tissue of the incision 
and 
patient has at least one of the following:  
a. Purulent drainage from the superficial incision 
b. Organisms isolated from an aseptically obtained culture of fluid or tissue from the 
superficial incision 
c. At least one of the following signs or symptoms of infection: pain or tenderness, 
localized swelling, redness, or heat, and superficial incision is deliberately opened by 
surgeon, unless incision is culture-negative 
d. Diagnosis of superficial incisional SSI by the surgeon or attending physician 
 Deep incisional SSI 
Infection occurs within 30 days after the operative procedure and the infection appears 
to be related to the operative procedure 
and 
involves deep soft tissues (e.g., fascial and muscle layers) of the incision 
and 
patient has at least one of the following: 
a. Purulent drainage from the deep incision but not from the organ/space component of 
the surgical site 
b. A deep incision spontaneously dehisces or is deliberately opened by a surgeon when 
the patient has at least one of the following signs or symptoms: fever (>38°C) or 
localized pain or tenderness, unless incision is culture-negative 
c. An abscess or other evidence of infection involving the deep incision is found on 
direct examination, during reoperation, or by histopathologic or radiologic 
examination 
d. Diagnosis of a deep incisional SSI by a surgeon or attending physician 
Organ/space SSI 
Infection occurs within 30 days after the operative procedure and the infection appears 
to be related to the operative procedure 
and 
infection involves any part of the body, excluding the skin incision, fascia, or muscle 
layers, that is opened or manipulated during the operative procedure 
and  
patient has at least one of the following: 
a. Purulent drainage from a drain that is placed through a stab wound into the 
organ/space 
b. Organisms isolated from an aseptically obtained culture of fluid or tissue in the 
organ/space 
c. An abscess or other evidence of infection involving the organ/space that is found on 
direct examination, during reoperation, or by histopathologic or radiologic 
examination 
d. Diagnosis of an organ/space SSI by a surgeon or attending physician 
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5.4. Data collection 
5.4.1. Data collection for nosocomial bloodstream infections 
Local infection control personnel (ICP) regularly received information about 
positive blood cultures from microbiology laboratory. Patients were followed 
up by trained local ICP for clinical confirmation using information from ward 
personnel and medical records. ICP recorded all necessary clinical and microbi-
ological data using a specific case-report form. All completed forms were au-
dited. Information routinely collected included age, gender, date of admission, 
date of the first positive blood culture, location of the patient at the onset of 
nosocomial BSI (ward), isolated microorganism(s) and antimicrobial suscepti-
bility, probable source of bacteremia/fungemia and antimicrobial therapy on the 
day of sampling. Comorbid clinical conditions were registered for adults from 
their medical records using Charlson weighted index of comorbidity on the 
basis of the patients’ International Classification of Diseases-10 coded 
diagnoses (150, 227). The following predisposing clinical conditions frequently 
described in literature (85, 87, 91) were documented: intravascular catheter, 
indwelling urinary catheter, presence of neutropenia (defined as an absolute 
neutrophil count of <500 cells/mm3, or a count of <1000 cells/mm3 with a pre-
dicted decrease to <500 cells/mm3), chemotherapy or surgery during the previ-
ous 30 days, organ transplantation, mechanical ventilation and total parenteral 
nutrition. Number of patient-days and number of admissions were received 
from hospital administrations. The use of CLs including umbilical catheters in 
PICU was documented daily. Survival status was recorded one week after the 
onset of nosocomial BSI and at hospital discharge.  
 
 
5.4.2. Data collection for surgical site infections 
All patient- and surgery-related data were collected prospectively by a single 
investigator (resident of obstetrics and gynecology). She visited patients during 
their hospitalization and explained the study purpose. Demographic infor-
mation, potential risk factors, and surgical indications collected from the medi-
cal records were recorded into a standardized collection form. Patient-related 
variables included age, nationality, parity, existing comorbidities (e.g., diabetes, 
preeclampsia, anemia, or chorioamnionitis), bacterial vaginosis during preg-
nancy, a preoperative condition assessed by ASA score, number of prenatal care 
visits, duration of ruptured membranes, duration of labor, preoperative stay, 
length of hospital stay in days, use of internal fetal monitoring, and number of 
vaginal examinations prior to CS at the hospital. Surgery-related variables in-
cluded emergency nature of the operation, indications for CS, duration of the 
operation, manual removal of the placenta, volume of blood loss, and antibiotic 
prophylaxis. The study subjects were postoperatively monitored for temper-




The investigators identified the infections during hospital stay or readmis-
sion or by postdischarge survey using the criteria of the CDC NNIS System 
(Table 10). The postdischarge survey was performed according to the modified 
methodology developed by Stockley et al. (228). Briefly, the patient received a 
questionnaire (Paper III, Figure) to be completed by physician (i.e., gynecol-
ogist or general practitioner) if problems developed regarding the wound or if 
endometritis developed after discharge. All study subjects were contacted by 
telephone 30 to 35 days after surgery (including those patients who had been 
diagnosed as having SSI during hospital stay). The patients were asked about 
their general health and the state of their surgical wound using a standard format 
based on the physician’s questionnaire. If a patient’s complaints indicated pos-
sible infection and the questionnaire had not been received from the physician, 
the investigator contacted either general practitioner or gynecologist for verbal 
confirmation of SSI. In case the completed questionnaire arrived and the CDC 
criteria were met, no further contact with the physician was established. If it 
was not possible to contact the patient by telephone, the outpatient medical 
records of those patients who were known to have returned to Tartu University 
Women’s Clinic were reviewed.  




5.5. Microbiological methods 
Blood cultures were obtained from patients with clinical signs of infection at the 
discretion of attending physician (study I and II). No specific instructions for 
blood culture testing (e.g., indication for culture, the timing of the culture, the 
volume of blood drawn for culture, the number of cultures) were provided to the 
participating hospitals in purpose of the study.  
Blood cultures were processed using BACTEC 9000 or BACTEC 9240 
(Becton Dickinson, Sparks, USA) at Tartu University Hospital and East-Tallinn 
Central Hospital; and BacT/ALERT 3D blood culture system (bioMerieux, 
Marcy l’Etoile, France) in the North Estonia Medical Centre. Bacterial isolates 
were identified by routine methods and verified by biochemical identification 
system VITEK2 Compact (since 2006 at Tartu University Hospital) or API tests 
(bioMerieux, Marcy l´Etoile, France). Antimicrobial susceptibility was deter-
mined in each centre by disc diffusion and/or E-tests (AB Biodisk, Solna, Swe-
den) according to Clinical and Laboratory Standards Institute recommendation 
(229, 230). Information was collected from laboratories on the total number of 





5.6. Data analysis and statistics 
Data were analyzed using Stata version 8.0 and version 9.0 (Stata Corp., Col-
lege Station, TX, USA) in study III and I, respectively; and SPSS version 17.0 
(IBM Corp., Armonk, NY, USA) in study II. To test differences between groups 
Fisher’s exact test or chi-square was used for categorical variables as appropri-
ate and Student’s t test was performed for continuous variables. All compari-
sons were unpaired, and all tests of significance were two-tailed. Odds ratios 
(ORs) with 95% CI were calculated. The binomial distribution was used to 
calculate 95% CI. A p value of .05 or less was considered to indicate statistical 
significance. Multiple logistic regression analysis was performed to adjust for 
potential confounders and to identify independent risk factors. Variables with 
statistically significant differences in univariate analysis were added to multiple 
logistic regression. 
SSI incidence (crude percentage of operations resulting in a SSI), BSI inci-
dence (number of BSI episodes per 100 admissions), BSI incidence density 
(number of BSI episodes per 1000 patient-days), CLABSI incidence density 
(number of CLABSI episodes per 1000 CL days), CL utilization ratio (number 
of CL days per patient-days) were calculated. As blood culture with CoNS may 
indicate either infection or contamination, the nosocomial BSI incidence and 
incidence density were also reported by excluding these microorganisms in 
study II. Case-fatality rate was defined as proportion of patients with nosocom-
ial BSI who died either within 7 days (7-day case fatality) or during the hospital 




Surveillance studies of nosocomial BSI were approved by the Research Ethics 
Committee of the University of Tartu, Estonia. Informed consent was not con-
sidered necessary because this was an observational study – the research in-
volved no risk to the subjects and welfare of subjects was not affected. 
Surveillance study of SSI following CS was conducted as part of the infec-
tion control activities at the Tartu University Hospital (Sihtasutuse Tartu Üli-
kooli Kliinikum infektsioonikontrolli teenistuse põhimäärus PKL-119, 2002 
Statutes of Infection Control Department of Tartu University Hospital PKL-
119, 2002). Information sheet (can be requested from the author) was given to 
the patients and contained statement that the study involved research, described 
the purpose and methods, the role of the participant, expected duration of the 
subjectʼs participation and explanation of whom to contact for answers to perti-
nent questions about the research. The study was also explained verbally to the 
patients and their verbal consent to participate was obtained. There were no 
interventions conducted for study purposes. The questionnaires were stored in a 
secure manner. 




6.1. Incidence of healthcare-associated infections 
6.1.1. Incidence of hospital-wide nosocomial bloodstream infections 
A total of 174 707 admissions and 971 687 patient-days occurred in three hos-
pitals over the study period. During the study period the overall blood culture 
sampling rate was 17 sets per 1000 patient-days (range, 13–21). In total, 549 
episodes of nosocomial BSI were recorded among 507 patients. The overall 
incidence of nosocomial BSI across the three hospitals was 3.1 per 1000 admis-
sions (range, 0.7–4.3) and the incidence density was 0.6 per 1000 patient-days 
(range, 0.2–0.8). 
Fifty-four percent of nosocomial BSI episodes were reported in ICUs, 24% 
in hematology units, 11% in surgical units, 7% in internal medicine units and 
4% in other units. The incidence density of nosocomial BSI per 1000 patient-
days was 5.9 (range, 4.4–7.4) and 0.3 (range, 0.1–0.4) in ICU and non-ICU 
wards respectively. Most (92%) nosocomial BSI occurred during the hospital 
stay in which it was acquired, 8% was related to previous hospitalisation. 
Over half of episodes (321, 58%) were primary (257 CLABSI, 64 of un-
known source) while 228 (42%) were secondary. Among secondary episodes 
the lower respiratory tract was the most common source (32% of all secondary 
cases). Central venous catheter and lower respiratory tract, as sources of noso-
comial BSI, were significantly more frequent among BSI acquired in ICU. As 
compared to ICU skin and soft tissue infections and nosocomial BSI of unknown 
origin were signifacntly more frequent in non-ICU departments (Table 11). 
 
 
6.1.2. Incidence of nosocomial bloodstream  
infections in pediatric intensive care unit 
During the study period 1363 patients were admitted to PICU including 745 
(55%) neonates. Through the years 2004–2006 the blood culture sampling rate 
was 268 sets per 1000 patient-days. In 89% of cases only one sample was taken. 
In total, 126 nosocomial BSI episodes were identified in 89 patients. The over-
all incidence of nosocomial BSI was 9.2 per 100 admissions (95% CI, 7.8–10.9) 
and the incidence density 12.8 per 1000 patient-days (95% CI, 10.7–15.2). 
Having excluded cases caused by CoNS, the respective rates were 5.1 (95% CI, 
4.0–6.4) and 7.1 (95% CI, 5.5–9.0). 
Multiple nosocomial BSI episodes occurred in 26 patients of which 17 pa-
tients had two, seven patients had three and two patients had four episodes.  
Primary BSI was diagnosed in 92 (73%) episodes, 67 of which were consid-
ered CL-associated. The median (IQR) duration of CL prior to CLABSI was 7 
(5–13) days. The overall CLABSI incidence density for neonates was 19.3 per 
1000 CL-days (95% CI, 14.7–24.9). Within birth weight groups there was a  
-fold variation in the incidence density of CLABSI with the highest rate (27.4 
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per 1000 CL-days, 95% CI, 19.0–39.0) among ELBW neonates. Among birth 
weight categories of 1001–1500, 1501–2500 and >2500 g, the respective inci-
dence densities were 13.3 (95% CI, 5.8–26.1), 14.8 (95% CI, 7.1–27.1) and 
15.1 (95% CI, 6.9–28.4) per 1000 CL-days. The CL utilization ratio was similar 
in different birth weight groups ranging from 0.41 to 0.57 (Paper II, Table II). A 
total of 34 (27%) episodes were defined as secondary, most frequently associ-




Table 11. Origin of 549 episodes of nosocomial BSI, stratified according to the clinical 
setting (ICU vs non-ICU wards) at East-Tallinn Central Hospital, the North Estonia 
Medical Centre and Tartu University Hospital in 20042005. 








Primary BSI     
  Catheter-associated 257 (47) 96 (37.9) 161 (54.4) 0.0001 
  Unknown 64 (12) 47 (18.6) 17 (5.7) <0.0001 
Secondary BSI     
  Lower respiratory tract  74 (13) 25 (9.9) 49 (16.6) 0.023 
  Skin/soft tissue 37 (7) 26 (10.3) 11 (3.7) 0.002 
  Surgical site  28 (5) 14 (5.5) 14 (4.7) 0.670 
  Urinary tract 27 (5) 14 (5.5) 13 (4.5) 0.538 
  Intraabdominal 26 (4) 9 (3.6) 17 (5.7) 0.229 
  Other 36 (7) 22 (8.7) 14 (4.7) 0.061 
 
 
6.1.3. Incidence of surgical site infections and postdischarge 
surveillance following cesarean section 
There were 310 cesarean sections performed among 2092 deliveries (14.8%; 
95%CI, 13.3 to 16.4) during the study period. Three hundred five patients were 
enrolled in the study (4 patients refused to participate and one patient died dur-
ing the operation due to a complication of underlying disease, rupture of an 
aortic aneurysm). 
During the study period 19 SSIs were identified: 14 patients developed inci-
sional (2 deep and 12 superficial) infections, 4 developed endometritis, and 1 
developed intraabdominal abscess. The overall infection rate was 6.2% (95% 
CI, 3.8 to 9.6). Of the 19 SSIs identified, 11 (57.9%) were diagnosed before and 
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8 (42.1%) after discharge. Of the latter, 2 patients were readmitted to the hos-
pital and 6 had SSIs detected by multi-method postdischarge surveillance.  
During the postdischarge surveillance, 280 patients were contacted by tele-
phone. Thirteen patients with SSIs were diagnosed in hospital (11 before dis-
charge and 2 on readmission). Fifteen of 267 patients described a possible in-
fection by telephone but only 6 cases were finally confirmed by the physician  
(4 with the questionnaire and 2 by personal contact). Information was obtained 
with chart review for 9 study subjects who could not be contacted by telephone 
and from whom a completed questionnaire was not received. None of them was 
diagnosed SSI (Figure). In this study, 16 of the 305 eligible patients were not 
available for any information during the postdischarge period. A combination of 
healthcare worker questionnaires, telephone calls, and chart reviews gave a 
postdischarge follow-up rate of 94.8%. 
Inpatient surveillance (including collecting surveillance data and explaining 
the purpose of the study) took approximately 20 minutes per patient; for tele-





Figure. Number of patient surveyed for SSI 30 days following CS by using multi-





6.2. Patient characteristics and risk factors 
6.2.1. Patient characteristics and potential factors predisposing  
to hospital-wide nosocomial bloodstream infection 
The mean (SD) age of patients with nosocomial BSI was 50 (25.5) years (range, 
<1–92 years). Forty-four episodes (8%) occurred in neonates (≤28 days of age) 
and 46 (10%) in pediatric patients (≤16 years of age). More than half (59%) of 
patients were male. The distribution of scores in the Charlson weighted index of 
comorbidity for the adult patients was 0 for 23%, 1 to 2 for 42%, 3 to 4 for 
23%, and 5 or higher for 12%. 
Intravascular devices were the most common potential predisposing factors: 
CLs were in place in 423 patients (77%) and arterial catheters in 254 (46%) 
patients. In total, 280 patients (51%) had two or more intravascular catheters. 
Other potential predisposing factors are presented in Table 12. 
The median (IQR) interval between admission and nosocomial BSI was 13 




6.2.2. Patient characteristics and potential  
factors predisposing to nosocomial bloodstream  
infection in pediatric intensive care unit 
Nosocomial BSI episodes occurred in 74 neonates; in eight infants; and in seven 
patients aged 1 up to 7 years; 56% of the patients were males. The most com-
mon underlying diseases in patients with nosocomial BSI are shown in  
Table 13. 
The majority (83%) of affected patients were neonates with 99 episodes 
(79% of all cases), with median (IQR) birth weight of 1000 g (740–1400) and 
median age at diagnosis of nosocomial BSI seven days (5.0–11.75). There were 
42 (57%) neonates with ELBW. The median (IQR) age of infants was 125.5 
days (110.5–163.25) at the onset of nosocomial BSI. 
All patients had at least one potential predisposing factor but intravascular 
devices were the most frequent: 70% had CL (median duration 8 days before 
onset of nosocomial BSI; IQR: 5–13.25); 48% arterial catheter (7 days; 5–9.5); 
57% had two or more intravascular catheters (Table 12). 
The median (IQR) length of PICU stay was 9 days (5–17) before and 21 










Table 12. Potential factors predisposing patients to nosocomial bloodstream infection at 
East-Tallinn Central Hospital, the North Estonia Medical Centre and Tartu University 
Hospital (20042005) and in pediatric intensive care unit of Tartu University Hospital 
(20042008). 
Potential factor No. of nosocomial BSIs (%) 




Central venous catheter 423  (77) 88 (70) 
Arterial catheter 254 (46) 60 (48) 
Two or more intravascular catheters 280 (51) 72 (57) 
Urinary catheter 279 (51) 9 (7) 
Mechanical ventilation 222 (40) 56 (44) 
Surgery within the preceding 30 days 220 (40) 41 (33) 
Total parenteral nutrition 132 (24) 48 (38) 
Chemotherapy  126 (23) 3 (2) 
Neutropenia 109 (20) 3 (2) 
 
 
Table 13. Occurrence of nosocomial bloodstream infections according to underlying 
disease on admission to pediatric intensive care unit of Tartu University Hospital in 
2004–2008. 
Underlying disease Neonates 
n=745 
Children  
> 28 days 
n=618 
Number of patients  
with nosocomial BSI 
episodes (%) 
Infection 43 100 31  (22) 
Respiratory system disease 494 72 23  (4) 
Cardiovascular system disease 71 79 5  (3) 
Trauma and accident 0 81 2  (2) 
Neurological disease 17 121 1 (1) 
Othera  120 165 27  (9) 
a other – includes hematological diseases, developmental defects requiring surgical repair 
(e.g. abdominal wall anomalies) 
 
 
6.2.3. Patient characteristics and risk factors for surgical site 
infection following cesarean section 
Among the study patients, there were 192 (63%) emergency and 113 (37%) 
elective CS performed. Indications for CS are provided in Table 14.  
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Table 14. Indications for cesarean cection in Women’s Clinic of Tartu University 
Hospital in 2002. 
Surgical indication No. of patients 
n=305 
% 
Fetal distress 72 24 
Breech and malpresentation 63 21 
Cephalopelvic disproportion 41 13 
Previous cesarean section 39 13 
Preeclampsia 25 8 
Dystocia 13 4 
Placenta previa, increta or placental abruption 12 4 
Othersa 40 13 
a Included maternal diseases, twin pregnancy, pelvic trauma 
 
 
Table 15. Analysis of risk factors for surgical site infections following cesarean section 
in Women’s Clinic of Tartu University Hospital in 2002. 
Risk factor SSI (n=19) No SSI (n=284)  
Mean  SD Mean  SD p value 
Age, years 27.7  6.5 28.5  5.9 .59 
Gestational age, weeks 39.2  2.6 38.6  2.6 .38 
Prenatal care visits  9.4  2.2  9.6  2.7 .75 
Preoperative stay, days  1.2  1.2  1.1  1.7 .08 
Vaginal examination prior to CS at 
hospital 
 2.6  1.7  1.9  1.8 .06 
Duration of labor, hours  6.0  8.5  2.8  4.7 .008 
Duration of ruptured membranes, 
hours 
10.5  18.2  5.4  21.2 .31 
ASA score   1.3  0.5  1.5  0.8 .18 
Duration of surgery, min 40.7  6.8 40.6  15.0 .97 
 n (%) n (%) OR (95% CI) 
Chorioamnionitis 2 (11) 2 (1) 16.6 (2.8–100.3) 
Internal fetal monitoring 2 (11) 3 (1) 11.0 (1.7–70.4) 
Surgical wound class III and IV 12 (63) 84 (30) 4.1 (1.6–10.7) 
Emergency CS 14 (74) 178 (63) 1.7 (0.6–4.6) 
Nulliparity 11 (58) 133 (47) 1.6 (0.6–3.9) 
Absence of antibiotic prophylaxis 7 (37) 96 (34) 1.1 (0.4–3.0) 





Two patients were excluded from the study during risk factor analysis because 
SSI developed more than 30 days after their CS. The characteristics of the sam-
ple are given in Table 14. Variables such as nationality, diabetes, preeclampsia, 
anemia, bacterial vaginosis during pregnancy, manual removal of the placenta, 
and volume of blood loss did not show significant differences between patients 
with and without SSI (data not shown). Univariate analysis identified that cho-
rioamnionitis, duration of labor, internal fetal monitoring, and surgical wound 
classes III and IV were associated with SSI (Table 15). Multiple logistic regres-
sion analysis identified three variables independently associated with increased 
risk for developing SSI: internal fetal monitoring (OR, 16.6; 95% CI, 2.2–
125.8; p = .007), chorioamnionitis (OR, 8.8; 95% CI, 1.1–69.6; p =.04), and 
surgical wound classes III and IV (OR, 3.8; 95% CI, 1.2–11.8; p = .02).  
Analysis of the use of antibiotic prophylaxis revealed that 163 (85%) of the 
emergency CS deliveries and 37 (33%) of the elective CS deliveries received 
prophylaxis. In two hundred twenty-three (73%) patients the guidelines were 
followed according to the current hospital policy for PAP. Seventy-five (25%) 
patients received antibacterial treatment after the surgery without any confirmed 
diagnosis of infection. 
The median (IQR) length of hospital stay for all patients was 5 (4.5–7) days. 
The median (IQR) period from surgery to detection of SSI was 5 (4–7) days. 
 
 
6.3. Microbiological aspects 
6.3.1. Microorganisms and their antimicrobial resistance causing 
hospital-wide nosocomial bloodstream infections  
A total of 593 pathogenic microorganisms were isolated. Of these, 315 (53%) 
were Gram- positive, 232 (39%) were Gram-negative aerobes, 35 (6%) were 
fungi and 11 (2%) were anaerobes. Polymicrobial BSI was observed in 44 epi-
sodes (8%). CoNS, Enterobacteriaceae and enterococci were the most fre-
quently isolated pathogens (Table 16). Nosocomial BSI due to Pseudomonas 
spp., CoNS and Candida spp. was significantly more common among ICU than 
non-ICU cases. Nosocomial BSIs in non-ICU patients were significantly more 
often caused by S. aureus and E. coli than ICU episodes. Among the 35 fungal 
isolates C. albicans was the most common (23 isolates, 66%). Among neutro-
penic patients the most frequent isolates were CoNS (28 of 113 isolates, 25%), 
E. coli (19 isolates, 17%) and enterococci (19 isolates, 17%).  
Antimicrobial resistance data are presented in Tables 17 and 18. The methi-
cillin-resistance among S. aureus isolates was 7%. One E. coli and three 
Klebsiella spp. produced ESBL. Of the Pseudomonas spp. isolates, 19%, 25%, 
30% and 44% were resistant to ceftazidime, meropenem, piperacillin/ 





Table 16. Most common causative pathogens in 549 episodes of nosocomial BSI strati-
fied according to clinical setting (ICU vs non-ICU ward) at East-Tallinn Central Hos-
pital, the North Estonia Medical Centre and Tartu University Hospital in 20042005. 







CoNS 152 (26) 57 (21) 95 (30) 0.018 
Enterococcus spp. 76 (13) 40 (15) 36 (11) 0.219 
Pseudomonas spp. 57 (10) 12 (4) 45 (14) 0.0001 
Staphylococcus aureus 54 (9) 35 (13) 19 (6) 0.004 
Klebsiella spp. 52 (9) 24 (9) 28 (9) 1.0 
Escherichia coli 49 (8) 35 (13) 14 (4) 0.0003 
Other Enterobacteriaceae 44 (7) 18 (7) 26 (8) 0.53 
Candida spp. 35 (6) 6 (2) 29 (9) 0.0004 
 
 
Table 17. Antimicrobial resistance among Gram-positive organisms most frequently 
isolated from patients with nosocomial BSI at East-Tallinn Central Hospital, the North 
Estonia Medical Centre and Tartu University Hospital in 20042005. 
Antibiotic Percentage of resistant isolates 






Oxacillin 83 (126/152) 7 (4/54) NT
Ampicillin NT NT 41 (31/76) 
Erythromycin 70 (95/135) 18 (9/50) 66 (33/50) 
Clindamycin 55 (65/119) 12 (6/49) NT 
Ciprofloxacin 73 (88/121) 6 (3/51) NT 
Gentamicin 76 (106/140) 2 (1/51) 58 (44/76)a 
Vancomycin 0 (0/152) 0 (0/54) 1 (1/76) 








Table 18. Antimicrobial resistance among Gram-negative organisms most frequently 
isolated from patients with nosocomial BSI at East-Tallinn Central Hospital, the North 
Estonia Medical Centre and Tartu University Hospital in 20042005. 
Antibiotic Percentage of resistant isolates  









Ampicillin 45 (18/40) 93 (41/44) 82 (27/33) NT 
Ampicillin/sulbactam 26 (12/47) 37 (19/52) 62 (26/42) NT 
Piperacillin/tazobactam 2 (1/48) 15 (8/52) 7 (3/42) 30 (16/54) 
Cefuroxime 3 (1/36) 31 (13/42) 58 (19/33) NT 
Cefotaxime 2 (1/44) 16 (8/49) 19 (8/42) NT 
Ceftazidime NT NT NT 19 (10/52) 
Cefepime 3 (1/35) 7 (3/43) 3 (1/33) 17 (6/36) 
Meropenem 0 (0/45) 2 (1/52) 0 (0/40) 25 (10/40) 
Imipenem NT NT NT 44 (15/34) 
Ciprofloxacin 4 (2/45) 8 (4/52) 2 (1/42) 22 (11/50) 
Gentamicin 4 (2/46) 10 (5/52) 5 (2/41) 32 (16/50) 
Amikacin 0 (0/32) 2 (1/42) 0 (0/33) 16 (8/50) 
NT- not tested 
 
 
6.3.2. Microorganisms and their antimicrobial resistance causing 
nosocomial bloodstream infections in pediatric intensive care unit 
In total, 136 isolates were recovered from 126 nosocomial BSI episodes, 8% of 
BSI episodes were polymicrobial. Gram-positive and Gram-negative micro-
organisms accounted for 60% and 35%, respectively. The most common 
pathogens were CoNS (43%) and Serratia marcescens (14%) (Table 19). From 
July 2005 to December 2009 an outbreak occurred with 149 patients colonized 
and 61 infected with S. marcescens.(231) MRSA caused an outbreak with 17 
affected patients (four BSI) in 2006–2007. There were five episodes of fun-
gemia (two Candida albicans, two Candida parapsilosis, one Candida gla-
brata), three of them in ELBW neonates (7% of all ELBW patients). 
Resistance to methicillin was detected in four out of seven of S. aureus iso-
lates (all isolated during the outbreak) and in the majority (86%) of CoNS iso-
lates. No resistance to vancomycin was detected among staphylococci and en-
terococci. Three of the 17 enterococci were ampicillin-resistant Enterococcus 
faecium. Among 39 Enterobacteriaceae, 88% were resistant to ampicillin, 65% 
to cefuroxime, 14% to gentamicin, 2% to ciprofloxacin and none to car-
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bapenems. Three isolates of Klebsiella pneumoniae, three S. marcescens and 
three Enterobacter cloacae (23% of all Enterobacteriaceae isolates) produced 
ESBL. All Candida spp. except C. glabrata were susceptible to fluconazole and 
none was resistant to amphotericin B. 
 
 
Table 19. Distribution of the 136 pathogens isolated in 126 episodes of nosocomial 





% of all 
isolates 
Gram-positive organisms 68 14 60 
  Coagulase-negative  
  staphylococci 
53 5 43 
  Enterococci 9 8 13 
  Staphylococcus aureus 6 1 5 
Gram-negative organisms 35 12 35 
  Serratia marcescens 13 6 14 
  Klebsiella pneumoniae 8 2 7 
  other Enterobacteriaceae 9 1 7 
  Acinetobacter baumannii 4 1 4 
  Pseudomonas aeruginosa 1 2 2 
Candida spp. 4 1 4 
Other 2 0 1 
 
 
6.4. Outcome of patients with  
healthcare-associated infections 
6.4.1. Outcome of patients with nosocomial bloodstream  
infection in hospital-wide surveillance study 
Overall, 157 of the patients with nosocomial BSI died during hospitalisation, 
accounting for in-hospital case-fatality rate of 31% (95% CI, 27.035.2). 
Among those 60 died within one week of onset of nosocomial BSI, accountig 
for 7-days case-fatality rate of 12% (95% CI, 9.215.0). The highest in-hospital 
case-fatality rates occurred in those with intra-abdominal and surgical site 
sources (Table 20). In-hospital case-fatality ranged from 15% for S. aureus to 
57% for enterococci (Table 20). Enterococci, Candida spp. and Pseudomonas 
spp. were significantly more frequently detected as pathogen of nosocomial BSI 
episodes among non-survivors.  
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A total of 258 patients (47%) were receiving appropriate antimicrobial ther-
apy on the day of sampling. The most common pathogens causing nosocomial 
BSI in episodes with inappropriate therapy were CoNS and enterococci in 30% 
and 15% of cases, respectively. 
 
 
Table 20. In-hospital case-fatality rates associated with origin of nosocomial BSI and 
most common causative pathogens at East-Tallinn Central Hospital, the North Estonia 







% (95% CI) % (95% CI) 
Intraabdominal 54a (33.473.4) Enterococcus spp. 57a (44.767.9) 
Surgical site  46a (27.566.1) Candida spp. 51a (34.068.0) 
Lower respiratory 
tract  
39 (28.051.2) Pseudomonas spp. 44a (30.757.6) 
Catheter-associated 31 (25.236.8) Other 
Enterobacteriaceae 
39 (24.454.5) 
Unknown 23 (13.835.7) Escherichia coli 29 (16.643.3) 
Urinary tract 19 (6.338.1) CoNS 24 (17.832.0) 
Skin/soft tissue 14 (4.528.8) Klebsiella spp. 21 (11.134.7) 
Other 39 (23.156.5) Staphylococcus aureus 15 (6.627.1) 
a Significantly (P < 0.05) more frequently detected as a source or as a pathogen of nosocom-
ial BSI episodes among non-survivors 
 
 
6.4.2. Outcome of patients with nosocomial bloodstream  
infection in pediatric intensive care unit 
Nine patients (10%), eight of them neonates, died during the hospital stay. Their 
nosocomial BSIs were caused by CoNS in 3 cases, S. marcescens in 4 cases, 
MRSA in one case and E.faecalis and S. marcescens in one case. The case-
fatality rate within 7 days after the first positive blood culture was 1%. Noso-
comial BSIs caused by Candida spp. were not associated with mortality in this 
study. 
Appropriate antimicrobial therapy was started on blood culture sampling day 
in 47% of nosocomial BSI episodes. The most common pathogens causing 
nosocomial BSI in episodes with inappropriate therapy were CoNS and Entero-





6.4.3. Outcome of patients with surgical site  
infection following cesarean section 
Patients with SSI had a longer mean (± SD) hospitalization time than did nonin-
fected patients (5.8 ± 0.3 vs 7.9 ± 1.5 days; p < .03). Two patients out of 19 





7.1. Factors influencing incidence of  
healthcare-associated infections  
7.1.1. Incidence of nosocomial bloodstream infections 
The incidence of hospital-wide nosocomial BSI recorded for the first time in 
Estonia was two times lower than in the SCOPE Project, one of the largest 
studies from the USA (3 vs 6 cases per 1000 admissions, respectively) (87). The 
overall hospital-wide incidence density of nosocomial BSI (0.6 per 1000 patient 
days) does not differ from other reported European studies where incidence 
densities varied from 0.6 to 0.8 per 1000 patient-days (84–86). Ammerlaan et 
al. reported the average incidence density of nosocomial BSIs from 0.6 to 1.9 
per 1000 patient-days in 14 hospitals from 9 countries between 1998 and 2007 
(83).  
A comparison of our PICU results with other studies is challenging because 
most studies have described epidemiology of nosocomial BSI either in PICU or 
NICU, but data from mixed units are limited. In addition, systematic review of 
strategies for reporting of neonatal nosocomial BSI identified a wide variability 
in reporting of BSI indicators and risk adjustment strategies which further 
makes comparison more difficult (232). In our study, the overall incidence of 
nosocomial BSI was 9.4 per 100 admissions, which is more than twice as high 
as those reported from PICU surveys in UK (3.9 per 100 admissions) and other 
centres in Europe (4.8 per 100 admissions) (26, 95). The nosocomial BSI inci-
dence density (12.8 per 1000 patient-days) was also higher than reported in 
Finland (3.2 and 2.5 in neonatology and PICU, respectively) (233). As our data 
represent a mixed PICU, the higher incidence of nosocomial BSI compared to 
non-neonatal PICU is understandable because neonates, especially ELBW in-
fants, are at the highest risk of nosocomial BSI (51, 91). In a study of neonatal 
infection surveillance network in England 26% of neonatal infections (93% of 
which were BSIs) occurred in ELBW (51).  
However, it is difficult to compare different countries as several methodo-
logical issues such as blood culture sampling rate, whether secondary BSI or 
whether more than one episode per patient is included, and which nosocomial 
BSI definition is used, may all affect the results (11, 234). Therefore comparing 
the facility’s infection rates to its own historical rates over time seems to be 
more meaningful.  
 
 
7.1.1.1. Blood culture sampling rate 
Our hospital-wide infection rates may not be strictly comparable because the 
mean number of blood culture sets in Estonia, 17 per 1000 patient days, was 
lower than that reported from most European countries during the study period 
(e.g., 42–54 in Finland, 38 in UK) (85, 235). The rate of nosocomial BSI is 
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influenced by the physicians’ threshold for ordering blood cultures; the volume 
of blood drawn for culture, the timing of the culture, the number of cultures 
taken, and the blood culture system (11). Schmitz et al. found considerable 
differences regarding preanalytic procedures of blood culture testing in four 
European countries (Italy, UK, France and Germany) (236). We did not produce 
any guideline for blood culture testing for the purpose of the study and all blood 
cultures were performed at the discretion of attending physician. Therefore, our 
results may be influenced by different blood culture practices between hospitals 
and our rate on nosocomial BSI can be underreported.  
In our PICU the mean number of blood culture sets per 1000 patient-days 
was high but in most cases only one sample was taken. This is an important 
issue to consider when defining nosocomial BSI caused by skin commensals. 
 
 
7.1.1.2. Definition of nosocomial bloodstream infection 
The definition is especially important in studies reporting high rate of noso-
comial BSI caused by skin commensals as in our PICU study. Usually it is rec-
ommended to include cases with at least two positive blood cultures with prob-
able contaminants and some studies with one positive culture require at least 5 
days of appropriate antimicrobial therapy (8, 51). In contrast to adults, only one 
blood culture is routinely drawn from premature babies because of technical 
difficulties and low circulating blood volumes. Modi et al. propose to add the 
requirement of 3 predefined clinical signs to have the best predictive accuracy 
for BSI caused by skin commensal (8). The German surveillance network for 
neonatal HAIs (NEO-KISS) in collaboration with clinicians has applied speci-
fied criteria for neonates to increase the acceptance of the surveillance data and 
its use (237). We have used previous US CDC definition of laboratory-con-
firmed BSI allowing us to diagnose nosocomial BSI with only one positive 
blood culture with CoNS (19). Sarvikivi et al. compared different nosocomial 
BSI definitions and found that due to the single blood culture policy in Finnish 
NICUs none of the blood cultures with skin commensals were confirmed by a 
second culture, and thus no cases met the revised CDC criteria for laboratory 
confirmed BSI (81, 234). The NEO-KISS criteria defining clinical findings in 
more detail diminished the number of identified cases by 15% (234). Therefore, 
our high rate of CoNS can be partly explained by difficulties to separate true 
pathogens from contaminants in this patient population. When CoNS cases were 
excluded from the analysis, the incidence and incidence density remained 
higher than in the UK network survey (5.1 versus 2.9 per 100 admissions) or in 
two tertiary care NICUs in London (7.1 versus 2.2 per 1000 patient-days) sug-
gesting that factors other than the interpretation of the positive blood culture 






7.1.1.3. Outbreak situation 
Surveillance in PICU which took place during the outbreaks of S. marcescens 
(231) and MRSA may have produced higher rates of nosocomial BSI caused by 
these organisms compared with surveillance performed when there were no 
outbreaks. S. marcescens, which has been described to cause long-lasting and 
difficult to control outbreaks, was the second most common pathogen of noso-
comial BSI in our study in contrast to other reports (93, 239). The outbreak in 
our study was eventually eliminated by screening mucosal colonization, co-
horting colonized and infected patients and by educating health care workers on 
infection control measures and hand hygiene procedures (231). Suboptimal 
nurse-to-patient staffing ratio (1:3, seen occasionally in our PICU and resulting 
in excessive workload for one nurse) may have played a role in the CLABSI 
rate and outbreaks (240). This ratio is a critical factor to ensure adherence to 
infection control measures (241). Leistner et al. demonstrated that high staffing 
levels are associated with a lower incidence of CLABSI and these results are 
congruent with other studies on staffing (169, 241). 
 
 
7.1.2. Incidence of surgical site infections  
following cesarean section 
The SSI incidence of 6.2% in our hospital is lower than incidence in most of the 
other studies that have used postdischarge surveillance, where rates have varied 
from 7.1% in Denmark to 23.5% in Brazil (Table 5). The comparison of our SSI 
rates with NNIS/NHSN System benchmarks is not meaningful because postdis-
charge surveillance is not required by the NNIS/NHSN System, but any com-
parison of SSI rates must take into account whether case-finding included the 
detection of SSI after discharge. Also in ECDC surveillance of SSI where the 
incidence was 2.9%, the intensity of postdischarge case-finding varies between 
European countries (16). Almost half of the SSIs (42.1%) were detected during 
postdischarge surveillance in our study. This finding belongs to the lower end of 
the range varying from 36 to 95% in reported studies using postdischarge sur-
veillance (Table 5). It might have been caused by the fact that our me-
dian length (5 days) of hospital stay was longer compared to other studies (e.g., 
3 days in England) (188, 191). In our study the median period from surgery to 
detection of SSI was as long as the median length of stay which enabled us to 
detect almost half of the cases already during the hospital stay. In case of stud-
ies with shorter length of stay it is not possible to find SSIs before discharge. 
The data suggest the necessity to perform postdischarge surveillance to obtain 
more accurate SSI rates.  
Noy and Creedy recommended in their study that when the rate is being cal-
culated, the number of responders, rather than the number of the total sample, 
should be used (242). As increasingly more infections emerge after discharge 
and in cases of a low response rate, inclusion of nonresponders may lower the 
infection rate and produce inaccuracies when compared with other healthcare 
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facilities. Thus, when these comparisons are being made, the denominator has 
to be taken into consideration. In our study, the response rate was high and the 
exclusion of nonresponders from the denominator would not have changed the 
results significantly (6.2% vs 6.6%). 
Majority of SSIs were superficial in our study. In some surgical environ-
ments, emphasis is placed on more serious infections, like deep infections and 
infections in organs/body cavities, as these give rise to increased patient suffer-
ing and higher costs for the health care system (190). Still, it is important to 
include the superficial infections into the surveillance as well, because these 
involve an additional burden for patients, increased use of antibiotics, and in-
creased costs, e.g., for doctor visits, as suggested by Eriksen et al (190). 
Monitoring superficial as well as deep infections provides higher sensitivity 
with which to examine the quality of care and detect potential problems with 
infection prevention (184). 
 
 
7.2. Risk factors for healthcare-associated infections 
7.2.1. Potential factors predisposing patients  
to nosocomial bloodstream infection 
Our nosocomial BSI studies were performed in different settings – the first 
study involved mainly adult patients and only PICU patients, mostly neonates, 
were included in the second study. Therefore some risk factors differ signifi-
cantly. In our study we did not have an external comparison group and thus we 
were unable to perform risk factor analysis. We were only able to identify po-
tential factors commonly described in literature such as underlying diseases and 
use of invasive devices (85, 87, 91). 
Comorbidities have an important role, because severely ill patients with 
multiple comorbidities are more likely to develop nosocomial infections. 
Charlson weighted index of comorbidity has been shown to be a useful meas-
urement of an underlying comorbidity and a good predictor of mortality of adult 
patients with BSI (149, 243). In our study more than one third of the adult pa-
tients had Charlson weighted index of comorbidity score of 3 or more. It has 
long been known that neutropenic patients are more likely to experience noso-
comial BSI (146). We investigated that 20% of the patients with nosocomial 
BSI had neutropenia in our hospital-wide study. In pediatric population gesta-
tional age and birth weight have a decisive role. Infants with the lowest birth 
weight are most at risk for nosocomial BSI due to their compromised immuno-
logical defense systems and multiple invasive procedures as reported in several 
studies (123–125). Also in our study the highest rate of CLABSI among ELBW 
infants became evident. 
Consistent with other studies, intravascular devices were the most common 
potential predisposing factors of nosocomial BSI in both populations (85, 87, 
91). It is possible that by using clinical and blood culture data we have overesti-
mated the importance of vascular catheters because device colonisation was not 
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always laboratory-confirmed. However, this approach corresponds more closely 
to clinical circumstances and is often used to compare nosocomial BSI rates in 
surveillance studies (244).  
According to our data most cases occurred in ICU or department of hema-




7.2.2. Risk factors for surgical site infection  
following cesarean section 
Data on a number of risk factors for the development of SSI were collected in 
the course of the study. The multiple logistic regression revealed three variables 
such as surgical wound classes III and IV, chorioamnionitis, and internal fetal 
monitoring independently associated with postcesarean SSI.  
We used modified wound classification where surgical wound class III was 
defined as rupture of membranes greater than 2 hours and class IV as purulent 
amniotic fluid (chorioamnionitis). Our finding is not surprising because chori-
oamnionitis usually results from migration of cervicovaginal flora through the 
cervical canal and rupture of membranes facilitates this process leading to 
higher risk for SSI. Several studies have reported a contaminated or dirty wound 
class (III and IV) as well as premature rupture of membranes and chorioamni-
onitis as a risk factor for SSI (190, 196, 199, 207, 245). Olsen et al. found that 
the odds of endometritis increased approximately 1.7-fold within 1 hour after 
rupture of membranes, but increased duration of rupture was only marginally 
associated with increased risk. Thus, the results were more consistent with in-
creased risk of endometritis associated with rupture per se, regardless of the 
duration (202). In a Cochrane review vaginal preparation immediately before 
CS significantly reduced the incidence of postcesarean endometritis, especially 
in women with ruptured membranes (218). Given these findings, preoperative 
vaginal preparation with povidone-iodine scrub should be considered prior to 
CS (218). 
Internal fetal monitoring, although this occurred in only a few cases, ap-
peared to predispose women strongly to SSI. Starr et al. also found an increased 
risk of developing endometritis in association with use of the intrapartum inter-
nal monitors (208). The pathophysiology is theoretically an ascending 
polymicrobial infection of cervical and vaginal organisms into the uterus with 
hematogenous spread through exposed edges of incised myometrium (208).  
A challenge exists to decrease the frequency of internal fetal monitoring. 
It is possible that well-known patient-related risk factors for SSI such as dia-
betes, preeclampsia or hypertension were not significant in our study due to 
frequent prenatal visits (mean 9.4 and 9.6 among patients with and without SSI, 
respectively). Killian et al. found that one of the significant risk factors for en-
dometritis following CS was having fewer than seven prenatal visits and there-
fore less opportunity for diagnostic testing (196). Hence, increased number of 
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prenatal visits is important to ensure primary prevention methods to prevent 
many perinatal complications, including postoperative infection (196). Unfortu-
nately, some data of the prepregnancy weight were missing and therefore we 
were unable to analyze obesity as an often-discussed risk factor. 
There were no significant differences regarding absence of PAP between 
patients with or without SSI. Estimating the protective effect of prophylactic 
antibiotics is problematic because antibiotics were continued after CS. A 
Cochrane Review from 2002 recommended single dose prophylactic antibiotics 
to all women undergoing CS after cord clamping (197). During the study period 
our hospital policy recommended prophylaxis to high risk groups only but in 
total of 73% of the patients the prophylaxis policy was followed. Since 2010 we 
recommend PAP for all patients with CS within one hour prior to incision. Ap-




7.3. Microbiological aspects 
7.3.1. Spectrum of microorganisms causing  
nosocomial bloodstream infections 
The most frequent cause of nosocomial BSI both hospital-wide as well in PICU 
was CoNS. The obvious predominance of CoNS is striking, but has also been 
similarly described in other studies (Table 4) (26, 51, 91, 95, 246). It is possible 
that our finding is overestimated due to blood culture contamination. As dis-
cussed above, determining whether a positive blood culture represents a noso-
comial BSI is usually not difficult with predominantly pathogenic organisms, 
but can be a considerable issue with common skin contaminants, such as CoNS 
(11). However, in preterm neonates with BSI CoNS may arise from gastro-
intestinal tract as have shown Soeorg et al. (247). They found molecular 
similarity between CoNS isolated from blood and gastrointestinal tract collected 
before BSI in more than half of the patients studied (18 out of 22) indicating 
that preterm neonates may harbour potentially invasive strains in gastrointesti-
nal tract before nosocomial BSI (247). On the other hand, these bacteria are also 
the most important cause of real CLABSIs as they may more likely colonize the 
catheter during insertion and use. In our PICU study 53% of nosocomial BSI 
were associated with CL and 67% of these were caused by CoNS. Since 2007 
we have implemented a guideline for the prevention of intravascular catheter-
related infections in Tartu University Hospital and hopefully applying current 
evidence for CL care leads to decreased incidence of nosocomial BSI. This 
phenomenon has been demonstrated by several studies reporting dramatic suc-
cess in reducing CLABSI (157, 160, 166). Bizzarro et al. observed also signifi-
cant reduction of CoNS-related BSI in NICU attributable to the implementation 
of targeted infection prevention and elimination of blood sampling via indwell-
ing catheters (248). 
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Enterococci were the second and third most common pathogens in hospital-
wide and PICU study, respectively. These findings are similar to other studies 
in which enterococci were among most common cause of nosocomial BSI (83, 
87, 249). Isolation of enterococci could indicate more serious condition of the 
patient and long-term treatment as they are relatively resistant to broad-spec-
trum antibiotics and thus can survive and overgrow after long-term treatment 
(250). According to the NHSN data the incidence density of CLABSIs caused 
by Enterococcus spp. has remained higher than for S. aureus since 2004 (89). A 
likely explanation for this finding is that CL insertion practices may be less 
effective at preventing BSIs caused by enterococci than staphylococci, because 
this infection may arise from the gastrointestinal tract through compromised 
mucosal barriers (89). 
The most commonly isolated Gram-negative organisms in our series (Enter-
obacteriaceae and Pseudomonas spp.) have also been among the leading Gram-
negative pathogens in other hospital-wide surveillance studies (83–85, 87). In 
contrast to studies conducted in PICU or NICU where S. marcescens has been 
rare or sporadic finding, this microorganism was the second most common 
pathogen in our PICU because of the outbreak (93).  
During recent years there has been an increase in the proportion of non-albi-
cans Candida spp. (136). We found that C. albicans was the most frequent fun-
gal species (66%) isolated from blood. One possible explanation to this may 
also be attributable to differences in the patient populations studied. Mostly 
non-hematological patients in ICU, probably without previous fluconazole 
prophylaxis dominated in our study. In contrast to studies where invasive Can-
dida infections are a major cause of morbidity and mortality in preterm neo-
nates, this pathogen was rare in our PICU study (251). This observation could in 
part be explained by the use of prophylactic fluconazole in high risk neonates 
and a conservative approach to empiric antibiotics. 
 
 
7.3.2. Antimicrobial resistance of pathogens  
causing nosocomial bloodstream infections 
During the hospital-wide study period, the rate of MRSA (7%) was higher than 
that identified in Nordic countries and the Netherlands but lower than rates 
reported from Central and Southern European countries (54). In the USA, data 
from hospitals participating in SCOPE showed that 41% of bloodstream S. au-
reus strains were methicillin resistant (87). Although our numbers are small in 
PICU study, high rate of MRSA was encountered because of the clonal spread 
of the outbreak strains. However, during the recent decade the percentage of 
invasive MRSA has been below 10% in Estonia (54). One vancomycin resistant 
Enterococcus sp. was isolated in hospital-wide BSI surveillance study. Vanco-
mycin resistant enterococci are still rare in Estonia and only few vanB gene 




Despite of the finding of only the 4 ESBL producing strains in hospital-wide 
BSI study, the overall ESBL percentage among Enterobacteriaceae was 23% in 
PICU. These data do not reflect the general reported epidemiology of antimi-
crobial resistance in Estonia (54). This is higher than the prevalence of ESBL-
producing invasive strains of K. pneumoniae (<12%) or E. coli (< 5%) in Esto-
nia during this period (54). In our PICU study ESBL was not common only in 
K. pneumoniae but also in E. cloaceae and S. marcescens strains. It can be ex-
plained with the outbreak in PICU as some ESBL outbreaks have been at-
tributed to the dissemination of plasmids carrying ESBL genes among strains of 
members of the family Enterobacteriaceae (252). One K. pneumoniae was 
reported to be resistant to meropenem in hospital-wide surveillance study. Car-
bapenemase production was not investigated in laboratories during the study 
time. However, the majority of carbapenem resistant strains isolated in Estonia 
have not been confirmed as carbapenemase producers in later studies (59).  
The resistance percentages of different antimicrobial agents among pseudo-
monas strains were higher in our hospital-wide surveillance study than those 
reported in the USA (SCOPE) and in European studies (85, 87). When compar-
ing P. aeruginosa EARS-Net data of different years high variation in resistance 
percentages without clear trends can be seen in Estonia (54). The reasons could 
be the small absolute number of invasive strains and changes in dominating 
clones in hospitals.  
Due to the fact that our data were collected mostly from tertiary hospitals in 
hospital-wide surveillance study and from PICU, resistance percentages are 
likely to reflect the microbiological epidemiology of patients with multiple 
comorbidities. Isolates from ICU patients may be expected to have higher levels 
of resistance than isolates from non-ICU patients (61). This emphasizes the 
importance of local data in order to avoid antibiotic resistance with appropriate 
infection control measures including antibiotic policy. 
 
 
7.4. Outcome of patients 
7.4.1. Case-fatality rate 
The in-hospital case-fatality rate observed in our hospital-wide surveillance 
study (31%) is consistent with previous investigations (87, 253). The BSIs sec-
ondary to abdominal and respiratory tract infections are usually associated with 
higher fatal outcome (39, 116). Similar finding was observed in our study as the 
case-fatality rate was the highest in nosocomial BSI secondary to intra-
abdominal site. Case-fatality rates were highest for infections caused by entero-
cocci (57%), Candida spp.(51%), and Pseudomonas spp. (44%). These are 
typical microorganisms associated with infection in severely ill patients. In-
hospital mortality associated with enterococcal BSI has been estimated between 
23–50% (250). In the SCOPE project the in-hospital mortality rates varied in 
etiology from 21% for CoNS to 39% for P. aeruginosa and Candida spp.(87)  
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In PICU the nosocomial BSI in-hospital case-fatality rate (10%) and the 
case-fatality rate within 7 days of the first positive blood culture (1%) were 
lower than those reported by Gray et al. for patients in PICU (26.5% and 
10.7%, respectively) (95). In US studies of pediatric patients and VLBW neo-
nates the BSI mortality was 14% and 18%, respectively (50, 91). The high rate 
of CoNS infections, which have a lower case-fatality, could help to explain the 
observed case-fatality in our study.  
 
 
7.4.2. Length of stay and readmissions 
We analysed the length of stay in our SSI study. It has been proved in several 
studies that one of the outcomes of SSIs is the increase in hospital stay (190, 
196, 212, 228). A significantly longer hospital stay also occurred in the current 
study once SSI was identified. Patients with more serious SSI may need addi-
tional outpatient visits, readmission or even reoperation (190). We do not have 
exact data about the number of additional outpatient visits, but two patients out 
of 19 with SSI were readmitted in our study. 
 
 
7.4.3. Appropriate antimicrobial therapy and  
perioperative antibiotic prophylaxis 
According to our data 53% of patients with nosocomial BSI were receiving 
inappropriate antimicrobial treatment in both studies. Empirical treatment of 
patients with BSIs has become more complicated in an era of increasing antimi-
crobial resistance. Many studies have found that bacterial resistance decreased 
the chance of early adequate therapy leading to increased mortality (116). The 
influence of inappropriate therapy on patients’ outcome falls beyond the scope 
of this thesis. In our studies the inappropriate therapy was given mainly for 
nosocomial BSI caused by low virulence Gram-positive microorganisms, like 
CoNS, that could also be an overestimated etiology as discussed above. Reduc-
ing the number of episodes with inadequate initial therapy would necessitate 
greater empiric use of glycopeptide antibiotics with the attendant risk of pro-
moting the emergence and spread of glycopeptide resistant enterococci and 
other Gram-positive bacteria. Nevertheless, the surveillance programs defining 
the species distribution and resistance patterns of microorganisms causing noso-
comial BSIs provide the basis for appropriate antimicrobial therapy and should 
be continued.  
In SSI study 25% of the patients received antibiotics postoperatively without 
any confirmed diagnosis of infection and in 73% of the patients hospital antibi-
otic prophylaxis policy was followed. Studies have shown that single-dose anti-
biotic prophylaxis is as effective as multiple doses of antibiotic (220). Hence, 
there is no need for the so-called extended antibiotic prophylaxis. The results of 
this study indicate the need for intervention to improve the rational use of anti-
biotic prophylaxis in accordance with the guidelines. 
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7.5. Surveillance of healthcare-associated  
infections in hospital 
7.5.1. Which method to use and what kind of  
healthcare-associated infections to study? 
HAI surveillance methods can be: active vs. passive; prospective vs. retrospec-
tive; hospital-wide vs targeted; patient vs. laboratory-based, or prevalence vs. 
incidence survey (3, 66).  
Prevalence surveys provide data at one particular pointing time, and are gen-
erally easy to conduct, relatively inexpensive and are not very time-consuming 
(9). Point prevalence studies have been performed at Tartu University Hospital 
once a year since 2003 and later in other Estonian hospitals as well (254). The 
ECDC requested that all member states should have carried out a point preva-
lence survey using a standardized protocol by June 2012. In four Estonian hos-
pitals participating in this survey the most common HAIs were SSIs (32% of all 
infections), LRTIs (28%), and UTIs (13%) (4). The disadvantage of this method 
is that prevalence surveys are biased in favour of HAIs of longer duration com-
pared to incidence surveys and are notably influenced by the duration of anti-
microbial treatment and the propensity to discharge patients (255). Perhaps the 
best uses of prevalence studies are to make valuable estimates of antimicrobial 
usage patterns, to evaluate the adherence to proper isolation practices, and to 
monitor practices related to high-risk procedures, such as use of vascular 
catheters (66). 
HAI incidence data have become the gold standard of HAI surveillance over 
the past 2 decades (255). Ideally, each hospital should have a continuous institu-
tion-wide prospective surveillance program assessing all HAIs for effective 
prevention but this requires careful consideration of the logistics of collecting 
the information and is often not feasible because of inadequate resources (9). 
Since the mid-1980s the trend has changed from continuously monitoring all 
patients for all HAIs in all hospital in favour of an approach that targets specific 
patient-care areas, patient-care processes, infection sites or infections caused by 
certain organisms, or (“priority-directed” surveillance) (66). Such programs are 
often restricted to ICU or other high-risk settings, such as oncology or neona-
tology. Infection preventionists must consider the advantages and disadvantages 
of different surveillance methods and the sensitivity of different case finding 
methods as they design their surveillance system (256).  
By measure/criterion that reflects both the relative frequency of the HAIs 
and the relative degrees of morbidity as expressed by the costs of extra days and 
extra ancillary services necessary to treat the HAIs, BSI would constitute the 
most serious problem (66). Although nosocomial BSIs have been studied exten-
sively, most of the studies and networks are focusing on ICU-acquired BSIs as 
we did in our PICU study. Our first study encompasses the entire hospitalized 
acute care population, rather than just those in ICU, in the three largest hospitals 
in Estonia. Besides primary BSIs we have also included all patients with 
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clinically significant nosocomial BSIs from any source or due to any microor-
ganism. The surveillance of nosocomial BSI may have some advantages com-
pared to other HAIs. First of all, it provides useful data on serious infections, 
causative organisms and their antibiotic resistance patterns to give feedback to 
different specialties (11). Hospital-wide nosocomial BSI surveillance is thought 
to be useful in monitoring trends including outbreaks, emerging multiresistant 
pathogens, and effects of intervention programs (10). Secondly, it is an easily 
defined condition (skin commensals excluded) and is less influenced by local 
laboratory testing practices and procedures. Laboratory-based surveillance 
methods have been used successfully to identify nosocomial BSI and methods 
that combine laboratory-based screening protocols with medical records review 
have performed well in hospital-wide surveillance models (257). In brief, the 
laboratory-based surveillance of nosocomial BSI provides valuable information 
with the smallest effort to collect hospital-wide HAI data. 
 
 
7.5.2. Should we study nosocomial bloodstream  
infections only in intensive care unit? 
Traditionally, nosocomial BSI or more specifically – CLABSI – surveillance is 
conducted only in ICUs because of the high use of CLs and perceived frequency 
of CLABSI. Weber et al. found that CDC-recommended ICU surveillance for 
CLABSI would have detected only 21% of 407 CLABSIs that occurred in the 
medical and surgical services of tertiary care university hospital (258). Re-
cently, studies have revealed similar CLABSI rates in both ICU and non-ICU 
departments (172). Hospital-wide catheter surveillance performed in Switzer-
land found that although cumulative CL-days were similar, the type, dwell time, 
and utilization of CLs in ICU and non-ICU settings were different (175). ICU 
CLs have a short dwell time but are utilised more often, whereas catheters in 
non-ICU settings show a reverse characteristic (175). Infection prevention 
measures targeting the post-insertion time of CLs are more likely to be 
successful in non-ICU settings, probably due to the fact that unjustified catheter 
use is more frequent and a further reduction of catheter dwell time in the ICU is 
unlikely (175).  
We found in our study that a quarter of nosocomial BSI cases occurred in 
hematology units justifying the surveillance outside ICU as well. 
 
 
7.6. What is the best method for postdischarge 
surveillance of surgical site infections? 
With the progressive reduction in the average hospital stay, an increasing per-
centage of some HAIs, most notably SSIs, become manifest after hospital dis-
charge (66). The best way to conduct postdischarge surveillance is still a matter 
of dispute according to the literature. Different postdischarge surveillance 
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surgeon or patient questionnaires, electronic search of patient records, telephone 
interviews, or automated telephony (182, 259). From ECDC SSI surveillance 
data, it appeared that three methods for obtaining post-discharge information 
were used most frequently in European countries: hospital surveillance staff 
obtains information from the patient using telephone or additional question-
naires (four networks); detection of postdischarge SSI on readmission to the 
hospital (three networks); hospital surveillance staff obtains information from 
the surgeon (three networks) (16). A systematic review of the methods used to 
identify SSI after discharge from hospital concluded that existing studies on the 
subject have so far failed to identify a valid, reliable method for identifying 
such infections (15). The ideal methodology should have a high follow-up rate, 
have high sensitivity and specificity, and be cost-effective. 
Several studies have used telephone interviews as a detection method for SSI 
(203, 260, 261). In the study performed by Taylor et al. the follow-up rate was 
93%, and it was concluded that this method of contact is feasible and effective 
(261). We agree with this because we could contact 92% of the patients by tele-
phone. Telephone questionnaire is a suitable method because approximately 
65% of the population owned a mobile during the study period and most of the 
patients were interested in participating in the surveillance (262). 
However, validity of the information obtained from patients is a matter of 
dispute in several research studies. Seaman and Lammers found that patients, 
despite using verbal or printed instructions, were unable to recognize infections 
(263). They reported that patients correctly identified their infections in only 11 
cases, whereas medical examiners diagnosed infection in 21 wounds, and called 
into question the validity of data obtained using patient-returned questionnaires 
or telephone surveys. Whitby et al., however, demonstrated that patients can 
accurately diagnose the absence of a wound complication, but are less accurate 
in diagnosing the presence of an infection (264). Patients frequently confuse 
serous discharge with pus and, therefore, this marker may overestimate infec-
tion rates. The results of our study also support the latter because nine of the 
patients self-reported the SSIs, which were not confirmed by a physician. 
Therefore, confidence in the results should be improved by gathering infor-
mation from several sources. Stockley et al. found that the combination of dif-
ferent methods like healthcare worker’s questionnaire, telephone calls and pa-
tient’s questionnaire is relatively simple to use and causes minimal inconven-
ience to patients and healthcare workers (228). We also used a multimethod 
approach described by Stockley et al. in combination with chart review with the 
follow-up rate of 95%.  
According to the literature the most accurate method to detect SSI is direct 
observation of surgical sites by trained professionals, e.g., infection control 
practitioners (182). However, in our study this was not feasible because we had 
to consider human and financial resources allotted for SSI surveillance. Never-
theless, in our survey all of the SSI diagnoses were determined by the investi-
gator to have met the CDC criteria. 
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Studies have indicated that antibiotic exposure is a sensitive indicator of an 
infection because relatively few serious infections are managed without antibi-
otics. Poor specificity (too many false-positive results) has been a major prob-
lem because antibiotics are so widely used after surgery for extended prophy-
laxis, empiric therapy of suspected infection, and treatment of infections other 
than SSI (191, 265, 266). In our study 75 patients without any confirmed infec-
tion diagnosis received antimicrobial treatment after CS. Therefore, we cannot 
use therapy as an indicator of SSI. Inappropriate use of antimicrobial agents not 
only adds to the cost of medical care, but also needlessly exposes the patient to 
potential toxicity and risks that promote the development and spread of antimi-
crobial resistance in healthcare facilities (267). 
Multi-method postdischarge surveillance has been described as cost-effec-
tive in several studies (203, 228, 242, 261). The method we used is not very 
time consuming. It is also more acceptable to patients because only those who 
have a problematic wound area need to go to the hospital for checkups. The data 
collection was simplified by the fact that most of the women returned to our 
clinic for postdischarge care. The same applies to the physicians; only physi-
cians whose patients have problems should take part in the study. The current 
study included the costs of labor, postage, and telephone calls. Computerized 
systems could reduce the time and costs required to perform surveillance by 
automated data collection from electronic medical records of microbiology 
results or antibiotic dispensing and/or administrative data (268). Yokoe et al. 
screened automated ambulatory medical records, hospital and emergency de-
partment claims, and pharmacy records and found that this method allows effi-
cient identification of postpartum infections not detected by conventional sur-
veillance (269). Leth et al. validated electronic surveillance of postcesarean SSI 
and found that sensitivities of SSIs diagnosed in hospital and postdischarge 
were 77.1% and 68.9%, and the specificities 99.5% and 98.2%, respectively 
(189). The completeness of electronic postdischarge surveillance depends on 
the likelihood that patients will return to the same healthcare provider. Although 
surveillance using claims data can be extended over multiple care providers, 
discharge codes and other indirect measures are in turn more likely to suffer 
from misclassification (268). Thus, a computer-based surveillance system may 
improve identification of in-hospital and postdischarge infections cost-effec-
tively but during the study period electronic medical records did not exist yet on 
a large scale in Estonia.  
We believe that our surveillance method improves confidence in results and 
the high response rate confirms the usefulness of this kind of the approach. 
Telephone interview would seem to be the most effective method of patient 
follow-up after discharge for this group of patients, although different ap-
proaches were not formally evaluated. Our postdischarge surveillance system 




7.7. Limitations of the study 
To describe epidemiology of hospital-wide nosocomial BSI in Estonia, we col-
lected data only from selected hospitals. Thus, not all Estonian hospitals (pri-
mary and secondary care level) were included and the results may be referral 
biased. Nevertheless, the number of blood culture sets in these three hospitals is 
approximately 75% of the total amount performed during the study period in 
Estonia according to data collected for the European Antimicrobial Resistance 
Surveillance System (unpublished data). Therefore, we believe that these results 
provide a reliable assessment of the epidemiology of nosocomial BSI in Estonia 
during the study period. 
Because of the limited resources we did not collect data on CL-days outside 
the ICU and we were unable to produce rates of CLABSI adjusted by CL use in 
our hospital-wide surveillance of nosocomial BSIs. Hospitals and their patient 
populations vary substantially, so it has become acceptable to calculate and 
report risk-adjusted infection rates (i.e., rates that are adjusted by important 
confounding factors). The rates can be adjusted by length of stay (e.g., inci-
dence density – the number of BSI per 1000 patient days); adjusted by exposure 
to devices (e.g., the number of BSI per 1000 central line-days) and stratified by 
unit type (e.g., ICU); and adjusted by severity of illness (e.g., neonatal BSI rates 
stratified by the birth weight) as we did in our PICU study (270). Risk adjust-
ment produces a more accurate estimate of risk at individual facilities (271).  
We used only laboratory confirmed methods in surveillance of nosocomial 
BSI, but infections are missed if cultures are not sent or if microorganisms fail 
to grow on culture media. Surveillance definitions for primary BSI distinguish 
those that are microbiologically documented from those that are not. The latter 
is known as clinical sepsis and can be reported as primary BSI. Some surveil-
lance systems or studies (mostly of neonates and infants) include this definition 
as well (99). However, detection of clinical sepsis requires prospective on-site 
surveillance and therefore demands more resources and the amount of work 
than laboratory-based method (272). In addition, the surveillance method to 
detect clinical sepsis will greatly impact the infection rate and make bench-
marking difficult (272). 
The limitation of the SSI study is that this is single hospital observation fo-
cusing on one type of surgical procedure and may not necessarily be extrapo-
lated to other centres. The Dutch national surveillance network, PREZIES, an-
alyzed data on 131 798 surgical procedures and the highest rate of SSI after 
discharge was found for appendectomy (79% of operations), followed by knee 
prosthesis surgery (64%), mastectomy (61%), femoropopliteal or femorotibial 
bypass (53%), and abdominal hysterectomy (53%) (273).With this approach it 
could be possible to discover the procedures for which postdischarge surveil-
lance is most essential, which may be important for efficient allocation of re-
sources on national or hospital level (273). However, while no universally ac-
cepted and validated method for postdischarge surveillance exists, the method 
used to identify postdischarge SSI on a local level is likely to be dependent on 
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existing resources, on the objective of surveillance, and on the nature of the data 
routinely available (15). Usefulness of our method for surgical procedures other 
than CS remains to be studied.  
 
 
7.8. Future considerations 
Prevention of HAIs has become a major focus of quality and patient safety pro-
grams in hospitals worldwide (3). We believe that our work has drawn attention 
to the problem of HAI and contributed to the development of surveillance ac-
tivities on hospital level during last 10 years in Estonia. For example, besides 
ongoing surveillance of hospital-wide nosocomial BSI and SSI following CS 
we have implemented surveillance of ICU-acquired infections (VAP, catheter-
associated UTI and CLABSI), Clostridium difficile infections, SSI following 
coronary artery bypass graft and multiresistant microorganisms at Tartu Univer-
sity Hospital. Once a year we perform hospital-wide point prevalence survey of 
HAI and antimicrobial use. Within 10 years (2004–2014) the overall incidence 
of HAI in adult ICU has decreased approximately three times at Tartu Uni-
versity Hospital.  
Unfortunately, the effective HAI surveillance system on national level is still 
lacking in Estonia. For example, ideally BSI monitoring should be continuous 
on-going data collection and data transfer, analysis, interpretation and reporting 
of data (preferably in real time) (11). Population-based studies have been pro-
posed as the best way of defining the epidemiology of BSI (78). In these de-
signs, all cases of disease occurring among residents of a defined geographical 
area are ascertained allowing to calculate incidence rates across selected age 
groups, race and sex (78). For example, Finland is the country that monitors the 
epidemiology of BSI overall on a nationwide basis. All clinical microbiology 
laboratories in Finland notify electronically information on positive blood cul-
tures. The unique national identity code of the patients allows linkage to data on 
vital status from the population registry and also makes it possible to conduct 
register linkage studies in which information on patient characteristics and hos-
pital stay are obtained from other national registries.(11) Estonia needs compre-
hensive HAI monitoring system on national level because knowledge of the 
incidence of HAI is important for setting healthcare and research priorities and 
for evaluating the effectiveness of preventative interventions. It is also im-
portant to monitor antimicrobial resistance and to detect and characterize re-
sistance mechanisms in real time. Unfortunately, many monitoring programs 
like EARS-Net rely on yearly reports that are relatively slow processes (11). We 
need our own system on national level to receive local data immediately. Up-to-
date information on species distribution and patterns of antimicrobial resistance 
is essential for projecting coverage by different antibiotic regimens and are thus 
crucial for appropriate clinical guidelines (11).  
Reliable HAI surveillance also depends on optimal and standardized sam-
pling practice. According to EARS-Net reports during the study period less 
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blood cultures were taken in Estonia than for example in Nordic countries 
(235). Thus implementation of appropriate sampling practices will increase the 
quality of our diagnostics as well as makes surveillance data more comparable. 
Specific guideline for obtaining blood cultures has been available at Tartu Uni-
versity Hospital since 2006 and the blood culture sampling rate per 1000 pa-
tient-days has increased during 10 years from 21 (2004–2005) to 32 (2014). The 
implementation of molecular typing of pathogens in routine laboratory service 
will enable to detect clonal spread and thus further improve HAI surveillance 
quality. 
Probably in the future traditional methodologies for HAI surveillance like 
review of medical records of all patients at risk for the specified HAI which are 
resource intensive and time consuming will be replaced with methods based on 
information technology (268). Various electronic databases exist within the 
healthcare setting and may be utilized to perform HAI surveillance (274). 
Automated systems would not be affected by cognitive biases, intentionally 
manipulating infection rates would be more difficult and likely transparent, and 
modelling strategies could be used to estimate probabilities of events (275). A 
further challenge for all forms of electronic surveillance is assessment of device 
presence, such as urinary catheters and CLs, as this determines the population at 
risk for device-related HAIs (268). In addition, the important challenges such as 
postdicharge surveillance and case-mix adjustment need to be addressed in the 
future (268).  
Future research should focus on the effects of infection control measures, 
e.g., to prevent outbreaks and to decrease incidence of CLABSI in PICU. Com-
pliance with different guidelines needs to be studied. Improving behaviour in 
infection prevention and control practice remains a challenge, and understand-
ing the determinants of healthcare workers’ behaviour is fundamental to de-
velop effective and sustained behaviour change interventions (276). 
As greater efforts are made to quantify and describe the characteristics of 
HAIs in Estonia, active surveillance, application of prevention interventions, 





1. In three major hospitals the overall hospital-wide incidence density of noso-
comial BSI did not differ significantly but the incidence was lower compared 
to other reported studies. The case-fatality rate was consistent with previous 
investigations. However, our rate of hospital-wide nosocomial BSI could be 
underreported due to low blood culture sampling rate. In our mixed PICU we 
observed higher incidence and incidence density of nosocomial BSI than 
reported previously partly because of outbreak situation and methodological 
issues such as case definition. Our case-fatality rates for patients in PICU 
were lower than those reported by other studies, which could be explained 
by the high rate of CoNS infections. Reporting nosocomial BSI rates with 
and without CoNS may provide more comparable data for benchmarking. 
Standardization of case definitions and methods including blood culturing 
could improve the quality of data, comparability of infection rates and 
outcomes between units and hospitals. 
2. In our research intravascular devices were the most frequent potential factors 
predisposing patients to nosocomial BSI. Approximately half of the episodes 
were CLABSI. In hospital-wide nosocomial BSI study half of the cases 
occurred in ICUs and a quarter in hematological wards. Efforts for 
prevention should be primarily targeted at CL insertion and care in high risk 
specialties such as ICU and hematology. 
3. The most commonly isolated causative organisms (CoNS followed by 
Enterobacteriaceae and enterococci) in our hospital-wide BSI surveillance 
study have been among the leading pathogens also in other studies. With the 
exception of relatively high antimicrobial resistance among Pseudomonas 
spp., the overall resistance patterns of Estonian hospital-wide nosocomial 
BSI pathogens were similar to those seen in Nordic countries and lower than 
in Central and Southern Europe. The differences in the distribution of 
infecting organisms in our PICU compared to previous reports, reflected the 
ongoing two outbreaks. High levels of antimicrobial resistance were detected 
in PICU, partly because of the outbreaks. This emphasises the need for local 
surveillance data in order to monitor trends, identify wards at risk, outbreaks 
and emerging resistant pathogens.  
4. The incidence of SSI following CS in our hospital was lower than rates from 
other studies that have used postdischarge surveillance. We found three 
variables associated with increased risk for developing SSI: internal fetal 
monitoring, chorioamnionitis, and surgical wound classes III and IV. A 
challenge exists to decrease the frequency of internal fetal monitoring and to 
treat chorioamnionitis as soon as possible. One third of the patients did not 
receive PAP, but new guidelines are recommending single dose prophylactic 
antibiotics to all women undergoing CS prior to incision. Following PAP 
recommendations can be one more possibility to decrease the incidence of 
SSIs in future. 
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5. Almost half of SSIs were detected during postdischarge surveillance high-
lighting the importance of this approach to obtain accurate rate of SSI. The 
multi-method approach using a combination of telephone calls, healthcare 
worker questionnaire, and outpatient medical records review resulted in high 
SSI follow-up rate and was not particularly time consuming. We can 
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10. SUMMARY IN ESTONIAN 
Haiglatekkesed infektsioonid Eestis –  
vereringe- ja operatsioonipiirkonna  
infektsioonide epidemioloogia ja järelevalve  
Viimastel aastakümnetel on haiglates üha rohkem tähelepanu pööratud ravi 
ohutusele, kuna see on oluline ravikvaliteedi problem (1). Haiglatekkene infekt-
sioon (HI) on seotud arstiabi osutamisega ning ning see avaldub patsiendil kas 
tervishoiuasutuses viibides või pärast sealt lahkumist. HI kaasneb suurem 
haigestumus, suremus ja tervishoiukulutuste kasv (2, 3). Euroopas diagnoosi-
takse vähemalt üks HI igal aastal 3,2 miljonil patsiendil (4). 
HI vältimises on oluline järelevalve, kuna see võimaldab leida parimaid 
meetodeid HI ennetamiseks (5). Paljudes maades on loodud riiklikud HI järele-
valvesüsteemid, kuid alates 2008. aastast on Haiguste Ennetamise ja Tõrje 
Euroopa Keskus käivitanud üleeuroopalise intensiivravitekkeste infektsioonide 
ja operatsioonipiirkonna infektsioonide (OPI) järelevalvesüsteemi (6). 
Kõige sagedasemad HI liigid on alumiste hingamisteede infektsioonid, OPI, 
kuseteede infektsioonid ja vereringeinfektsioonid (VRI) (4). HI haigestumus 
varieerub erinevate patsiendigruppide lõikes sõltuvalt riskifaktoritest nagu näi-
teks patsiendi enda tervislikust seisundist (vanus, kaasuvad haigused jm) kui ka 
invasiivsete vahendite kasutamisest. Kõige rohkem on ohustatud intensiivravi-
osakonna patsiendid. Lastel on HI suurim risk vastsündinute- ja lasteinten-
siivravi osakonnas. Nendes osakondades on kõige sagedasem infektsioon VRI, 
mis põhjustab lisaks suuremale haigestumusele ning suremusele ka kaugtaga-
järgi nagu arenguhäireid ja kasvupeetust (8).  
Samas on HI järelevalve oluline ka väljaspool intensiivravi osakonda, kuid 
kõikide HI järelevalvet on keeruline ja kulukas teostada (9). Eelistatud võiks 
olla ülehaiglaline VRI järelevalve, kuna need esindavad infektsioonide spektri 
kõige tõsisemat osa (10). Ülehaiglaline VRI järelevalve võimaldab jälgida 
haigestumuse trende, välja selgitada riskiosakondi, avastada puhanguid ja resis-
tentseid mikroorganisme ning hinnata HI vältimismeetodite rakendamise mõju 
(10). Haigustekitajate spektri ja ravimresistentsuse järelevalve on abiks ka anti-
mikroobse ravi juhendite koostamisel (11).  
Kui VRI on üheks kõige raskema kuluga infektsiooniks, siis OPI on üheks 
sagedasemaks (12, 13). Euroopa antibiootikumide kasutamise ja HI hetkelevi-
musuuringus oli OPI sageduselt teine infektsioon (19,6% kõikidest HI) (4). 
Kuna operatsoonijärgne haiglasviibimise aeg jätkuvalt lüheneb, on haiglajärgne 
järelevalve muutunud üha olulisemaks, et saada täpsemaid tulemusi OPI haiges-
tumuse kohta (14). Hinnatud on mitmete haiglajärgsete OPI järelevalvemeeto-
dite efektiivsust, kuid sellest hoolimata ei ole leitud ühtegi universaalselt 
aktsepteeritavat strateegiat nimetatud infektsioonide jälgimiseks (15). Haigla-
järgsed järelevalvemeetodid ja -tegevused erinevad riikide lõikes (4). 
Enne 2002. aastat oli Eestis uuritud vaid HI mikroorganisme nagu Acineto-
bacter baumannii, Staphylococcus aureus ja Escherichia coli (17, 18). Eestis ei 
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olnud ühtset HI järelevalvesüsteemi ja puudus ülevaade HI epidemioloogiast. 
Selle lünga täitmiseks alustasime keisrilõikejärgse OPI uurimisega, kuna keisri-
lõige on üks kõige sagedasematest operatsioonidest maailmas (216, 224). Tei-




Uurimistöö peamiseks eesmärgiks oli välja selgitada HI epidemioloogia Eestis 
täiskasvanutel ja lastel ning aidata kaasa järelevalvesüsteemide loomisele haig-
lates ning luua uusi teadmisi ja oskusi HI ennetamiseks tulevikus. 
Konkreetsed eesmärgid: 
1. Selgitada välja VRI haigestumus ja surmavusmäär kolmes suuremas 
haiglas 
2. Selgitada välja VRI teket soodustavad faktorid ning riskipiirkonnad (osa-
konnad) 
3. Selgitada välja VRI etioloogia ja mikroorganismide antibiootikumresis-
tentsus 
4. Selgitada välja keisrilõikejärgse OPI haigestumus ja riskifaktorid Tartu 
Ülikooli Kliinikumi naistekliinikus 
5. Hinnata haiglajärgse OPI kombineeritud järelevalvemeetodi sobivust 
 
 
Patsiendid ja meetodid 
Ülehaiglalise VRI uuringu (1. uuringu) viisime läbi kolme Eesti haigla (Ida-
Tallinna Keskhaigla, Põhja-Eesti Regionaalhaigla, Tartu Ülikooli Kliinikum) 
aktiivraviosakondades aastatel 2004–2005. VRI 2. uuringu viisime läbi TÜK 
lasteintensiivravi osakonnas (LIRO) aastatel 2004–2008. Mõlemasse uuringusse 
kaasasime kõik patsiendid, kelle laboratoorselt kinnitatud VRI vastas USA 
Haiguste Ennetamise ja Tõrje Keskuse definitsioonile. LIRO uuritavateks olid 
patsiendid, kel oli diagnoositud intensiivravi osakonna tekkene VRI. Andmeid 
kogusid nende haiglate infektsioonikontrolliarstid ja -õed prospektiivselt 
vastavalt standardiseeritud uuringuprotokollile. LIRO kogusime ka igapäevaselt 
tsentraalveenikateetri kasutamise andmeid. Verekülvid võeti raviarsti 
korraldusel vastavalt kliinilisele näidustusele. Verekülvidest isoleeritud 
patogeenid identifitseeriti ja antibiootikumtundlikkus (disk- ja gradientdi-
fusioonimeetodil) määrati iga haigla laboris. Uuritud verekülvide arvu saime 
laboritest. 
Keisrilõikejärgse OPI uuringu (3. uuringu) viisime läbi TÜK naistekliinikus 
kõikidel nii erakorralise kui plaanilise keisrilõikega sünnitanud patsientidel 
aastal 2002. Kogusime andmeid võimalike riskifaktorite kohta. Kõigile patsien-
tidele andsime enne haiglast väljakirjutamist küsimustiku ja palusime selle anda 
arstile täitmiseks juhul, kui tekib OPI. 30–35 päeva pärast operatsiooni helista-
sime patsientidele. Kui jäi kahtlus OPI-le ning arst ei olnud tagastanud küsi-
mustikku, võtsime ühendust raviarstiga kinnitamaks OPI olemasolu või saime 
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kinnituse ambulatoorsest kaardist. OPI diagnoosisime 30 päeva jooksul pärast 
keisrilõiget vastavalt USA Haiguste Ennetamise ja Tõrje Keskuse definit-
sioonile kas haiglas pärast operatsiooni, rehospitaliseerimisel või haiglajärgse 
järelevalve meetodi abil. 
Statistiliseks analüüsiks kasutasime tarkvara STATA versioon 8.0 ja 9.0 ning 
SPSS versioon 17.0. Arvutasime OPI esmashaigestumuse, VRI esmashaiges-
tumuse ja haigestumuskordaja (LIRO vastavad näitajad ka koagulaasnega-
tiivseid stafülokokke kaasates ja välja arvates), TVK seotud VRI haigestumus-
kordaja, tsentraalveenikateetri kasutusmäära, VRI surmavusmäära. OPI riski-




Ülehaiglaline VRI uuring (1. uuring) 
Uuringuperioodil võeti 1321 verekülvi 1000 voodipäeva kohta kolmes Eesti 
haiglas. Diagnoosisime kokku 549 VRI episoodi 507 patsiendil. VRI esmas-
haigestumus 100 hospitaliseerimise kohta oli 3,1 (haare, 0,74,3) ja haiges-
tumuskordaja 1000 voodipäeva kohta oli 0,6 (haare, 0,2–0,8). Patsientide kesk-
mine vanus oli 49 a. (haare, <192 a.) ning 59% olid mehed. Patsientidest 44 
(8%) olid vastsündinud ja 46 (10%) lapsed vanuses ≤16 a. Kõikidest VRI 
episoodidest 54% tekkis intensiivravi ja 24% hematoloogia osakondades. Kõige 
sagedasemaks VRI lähtekohaks (47%) oli tsentraalveenikateeter ja alumised 
hingamisteed (13%). Kõige sagedasemaks potentsiaalseks VRI riskifaktoriks 
olid veresoonesisesed vahendid: tsentraalveenikateetreid kasutati 77% ja 
arterikanüüle 46% patsientidest. 
Kolme haigla VRI haigustekitajatest (593 tüve) moodustasid Gram-posi-
tiivsed aeroobid 53%, Gram-negatiivsed aeroobid 39%, seened 6% ning 
anaeroobid 2%. Kõige sagedasemad mikroobid olid koagulaasnegatiivsed 
stafülokokid (26%), Enterobacteriaceae (24%), enterokokid (13%) and Pseu-
domonas spp. (10%). VRI episoodidest 8% olid polümikroobsed. Staphylo-
coccus aureus tüvedest 7% olid metitsilliin-resistentsed. Üks Escherichia coli ja 
3 Klebsiella pneumoniae tüve produtseerisid laia toimespektriga beeta-lakta-
maasi. Pseudomonas spp. tüvedest 19%, 25%, 30% ja 44% olid vastavalt 
resistentsed tseftasidiimile, meropeneemile, piperatsilliin/tasobaktaamile ning 
imipeneemile. 
Üldine surmavusmäär haiglas oli 31% varieerudes 15% S. aureus poolt 
põhjustatud VRI korral kuni 57% enterokokkide puhul. Intraabdomiaalse ja 
operatsioonipiirkonnast lähtunud VRI korral oli surmavusmäär kõige suurem 
võrreldes teiste lähtekohtadega. Seitsme päeva surmavusmäär oli 12%. 
 
Lasteintensiivravi osakonna VRI uuring (2. uuring) 
Aastatel 2004–2006 võeti LIRO-s 268 verekülvi 1000 voodipäeva kohta, 89% 
juhtudest võeti ainult üks verekülv. Uuringuperioodil diagnoosisime 126 VRI 
episoodi 89 patsiendil. VRI esmashaigestumus 100 hospitaliseerimise kohta oli 
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9,2 (95% usaldusvahemik 7,810,9) ja haigestumuskordaja 1000 voodipäeva 
kohta 12,8 (95% usaldusvahemik 10,715,2) . Kui me arvasime tulemustest 
välja koagulaasnegatiivsete stafülokokkide kui võimalike verekülvi kontami-
nantide poolt põhjustatud VRI, siis olid vastavad tulemused 5,1 (95% usaldus-
vahemik 4,06,4) ja 7,1 (95% usaldusvahemik 5,59,0). Patsientide hulgas oli 
74 vastsündinut, 8 imikut ja 7 last vanuses 17 aastat. Vastsündinute seas oli < 
1000 g sünnikaaluga patsiente 57%. 
Kõige rohkem esines primaarset VRI (92 episoodi), nendest 67 olid tsent-
raalveenikateetriga seotud infektsioonid. Vastsündinute tsentraalveenikateetriga 
seotud VRI haigestumuskordaja oli 19,3 1000 tsentraalveenikateetripäeva kohta 
(95% usaldusvahemik 14,7–24,9) ning kõige kõrgem vastav näitaja (27,4) 
esines < 1000 g sünnikaaluga vastsündinutel. Kõige sagedasemaks potentsiaal-
seks VRI riskifaktoriks olid veresoonesisesed vahendid: tsentraalveenikateetreid 
kasutati 70% ja arterikanüüle 48% VRI juhtude korral.  
VRI haigustekitajatest (136) moodustasid Gram-positiivsed ja Gram-
negatiivsed mikroorganismid vastavalt 60 ja 35%. Kõige sagedasemad olid 
koagulaasnegatiivsed stafülokokid (43%) ja Serratia marcescens (14%). 
Viimase tekitaja suur sagedus oli tingitud puhangust uuringuperioodil. Neli S. 
aureus tüve seitsmest olid metitsilliin-resistentsed, mis kõik kuulusid metit-
silliin-resistentse S. aureus puhangu tüvede hulka aastatel 2006–2007. Kolm 
Klebsiella pneumoniae, 3 S. marcescens ja 3 Enterobacter cloacae tüve (23% 
kõikidest Enterobacteriaceae tüvedest) produtseerisid laia toimespektriga 
beeta-laktamaasi. 
Üheksa patsienti (10%), nendest 8 vastsündinut, suri haiglasviibimise jook-
sul. Seitsme-päeva surmavusmäär oli 1%. 
 
Keisrilõikejärgse OPI uuring (3. uuring) 
Uuringuperioodil sünnitas 2092 naist, nendest keisrilõike teel 310 (14,8%; 95% 
usaldusvahemik, 13,316,4). Uuringus oli nõus osalema 305 patsienti. Peamine 
põhjus keisrilõikega sünnitamiseks oli loote distress (24%). 
OPI tekkis 19 patsiendil (6,2 %; 95% usaldusvahemik, 3,8–9,6): 4 endo-
metriiti, 1 intraabdominaalne abstsess, 14 haavainfektsiooni. OPI diagnoosisime 
11 patsiendil haiglas ja 8 patsiendil haiglajärgselt, kellest 2 rehospitaliseeriti.  
Pärast haiglast lahkumist helistasime 267 patsiendile, kellel OPI ei olnud 
diagnoositud haiglas. Nendest 15 kirjeldas võimalikku infektsiooni, kuid ravi-
arsti kinnitas seda kuuel juhul. Üheksa patsiendi kohta, kellele ei õnnestunud 
helistada ega kelle puhul ka raviarst ei tagastanud küsimustikku, saime infor-
matsiooni ambulatoorsest kaardist. Pärast haiglast lahkumist saime telefoni-
küsitluse, küsimustiku ja ambulatoorsete kaartide abil informatsiooni 95% 
patsientide kohta. Haiglajärgselt diagnoosisime 42% OPI juhtudest. 
Leidsime kolm statistiliselt olulist riskifaktorit: invasiivne loote monitooring 
(šansside suhe 16,6; 95% usaldusvahemik 2,2–125,8), koorioamnioniit 
(šansside suhe 8,8; 95% usaldusvahemik 1,1–69,6) ja kirurgiline haavaklass III 
ja IV (šansside suhe 3,8; 95% usaldusvahemik 1,2–11,8). Perioperatiivset 
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antibiootikumprofülaktikat ei tehtud 103 patsiendile. Uuringuperioodil kehtinud 




1. Võrreldes mujal läbiviidud uuringute tulemustega ei erinenud kolme 
haigla VRI haigestumuskordaja ja surmavusmäär märkmisväärselt, kuid 
esmashaigestumus oli madalam. Samas võeti uuringuperioodil vähe 
verekülve, mis võis mõjutada tulemust. Lasteintensiivravi osakonna VRI 
haigestumus oli kõrgem kui eelnevalt avaldatud uuringutes. Seda võisid 
mõjutada nii kaks bakteriaalset puhangut uuringuperioodil kui ka VRI 
definitsiooniga seotud metodoloogilised probleemid. Surmavusmäär võr-
reldes teiste lasteintensiivravi osakonnas tehtud uurimistöödega oli 
madal, kuid seda võis mõjutada suur koagulaasnegatiivsete stafülo-
kokkide poolt põhjustatud VRI osakaal. Nii koagulaasnegatiivseid sta-
fülokokke kaasavad kui välistavad VRI tulemused võiksid parandada 
andmete võrreldavust. Definitsioonide ja meetodite, sealhulgas verekülvi 
võtmise praktika, standardiseerimine parandab andmete kvaliteeti ning 
tulemuste osakondade- ning haiglatevahelist võrreldavust. 
2. Mõlemas VRI uuringus esines potentsiaalsetest VRI riskifaktoritest kõige 
rohkem veresoonesiseseid kateetreid ja kanüüle. Peaaegu pooled epi-
soodid olid tsentraalveenikateetriga seotud vereringeinfektsioonid. Üle-
haiglalises VRI uuringus diagnoosisime pooled juhud intensiivravi ja 
neljandik juhtudest hematoloogia osakondades. Sellest lähtuvalt tuleks 
riskiosakondades nagu intensiivravi ja hematoloogia pöörata erilist tähe-
lepanu veresoonesiseste vahendite sisestamisele ja hooldusele. 
3. Ülehaiglalise VRI uuringu haigustekitajate spekter sarnanes teiste uurin-
gute tulemustega. Üldine antibiootikumresistentsus (v.a. kõrge Pseudo-
monas spp. antibiootikumresistentsus) oli sarnane Põhjamaadele ja mada-
lam kui Kesk- ja Lõuna-Euroopas. Lasteintensiivravi osakonna VRI 
haigustekitajate spektrit ja antibiootikumresistentsust mõjutasid kaks 
bakteriaalset puhangut. See rõhutab kohaliku järelevalve olulisust, sest 
see võimaldab jälgida haigestumuse trende, välja selgitada riskiosakondi, 
avastada puhanguid ja resistentseid mikroorganisme. 
4. Keisrilõikejärgse OPI esmashaigestumus oli madalam võrreldes teiste 
haiglajärgset järelevalvet kasutanud uuringute tulemustega. Riskitegu-
riteks osutusid korioamnioniit, invasiivne loote jälgimine ja kirurgiline 
haavaklass III ja IV. OPI edaspidiseks vähendamiseks tuleks piirata inva-
siivset loote jälgimist ja ravida korioamnioniiti võimalikult varakult. 
Kolmandikule patsientidest ei tehtud perioperatiivset antibiootikumprofü-
laktikat, kuid praegu kehtivad PAP juhendid soovitavad seda kõikidele 
keisrilõikega sünnitajatele. PAP juhendite järgimine oleks edaspidi üheks 
võimaluseks, et veelgi vähendada operatsioonipiirkonna infektsioone. 
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5. Peaaegu pooled OPI juhud diagnoosime pärast haiglas viibimist, mis 
rõhutab haiglajärgse järelevalve olulisust. Meie valitud meetod osutus 
sobivaks keisrilõikejärgse OPI haiglaväliseks järelevalveks ning oli 
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